書籍詳細

第1章 歴史と変遷

P.17 掲載の参考文献

• 1) Lepine JP, Gastpar M, Mendlewicz J et al:Depression in the community:the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29, 1997

• 2) Murray CJL, Lopez AD (Eds):The global burden of disease:A comprehensive assessment of mortality and disability from diseases, Injuries and risk factors in 1990 and projected to 2020. Harvard Univ Press 1996

• 3) Kuhn R:Uber die Behandlung depressiver Zustande mit einem Iminodibenzylderivat (G22355). Schweiz Med Wochenschrift 87:1135-1140, 1957. {立山萬里<訳>:イミプラミン. 精神病治療薬の原点 (保崎秀夫監修, 八木剛平編集), 金剛出版, 東京, 1987, pp. 70-83}

• 4) Glowinski J, Axelrod J:Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compound. Nature 204:1318-1319, 1964
  pubmed

• 5) Carlsson A, Fuxe K, Ungerstedt U:The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 20:150-151, 1968
  pubmed

• 6) Westenberg HG:Pharmacology of antidepressants:selectivity or multiplicity? J Clin Psychiatry 60 (Suppl 17):4-8, 1999

• 7) Moller HJ:Are all antidepressants the same? J Clin Psychiatry 61 (Suppl 6):24-28, 2000

• 8) American Psychiatric Association:Practice Guideline for the Treatment of Patients with Major Depressive Disorder (Revision). Am J Psychiatry 157 (Suppl), 2000

• 9) Vetulani J, Sulser F:Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 9;257 (5526):495-496, 1975

• 10) Peroutka SJ, Snyder SH:Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 3;210 (4465):88-90, 1980

• 11) Klein DF, Fink M:Psychiatric reaction patterns to imipramine. Am J Psychiatry 119:432-438, 1962
  pubmed

• 12) Coppen A:The biochemistry of affective disorders. Br J Psychiatry 113:1237-1264, 1967
  pubmed

• 13) 本橋伸高:選択的セロトニン再取り込み阻害薬. 日本臨床 59:2001-2008, 2001
  Medical*Online

• 14) Crane GE:The psychiatric side-effect of iproniazid. Am J Psychiatry 112:494-501, 1956
  pubmed

• 15) Kline NS:Clinical experience with iproniazid (Marsilid). J Clin Exper Psycho Path 19 (Suppl 1):72-78, 1958

• 16) Gaddum JH:Chemical transmission in the central nervous system. Nature 197:741-743, 1963
  pubmed

• 17) Schildkraut JJ:The catecholamine hypothesis of affective disorders:a review of supporting evidence. Am J Psychiatry 122:509-522, 1965
  pubmed

• 18) Gorman JM:Mirtazapine:clinical overview. J Clin Psychiatry 60 (Suppl 17):9-13, 1999

• 19) Brown MC, Nimmerrichter AA, Guest JF:Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. Eur Psychiatry 14:230-244, 1999
  pubmed

• 20) Montgomery SA:Reboxetine:additional benefits to the depressed patient. J Psychopharmacol 11 (Suppl 4) S9-S15, 1997

• 21) Dubini A, Bosc M, Polin V:Noradrenaline-selective versus serotonin-selective antidepressant therapy:differential effects on social functioning. J Psychopharmacol 11 (Suppl 4) S17-S23, 1997

• 22) Kent JM:SNaRIs, NaSSAs, and NaRIs:new agents for the treatment of depression. Lancet 355:911-918, 2000
  pubmed

• 23) Ferguson JM:The effects of antidepressants on sexual functioning in depressed patients:a review. J Clin Psychiatry 62 (Suppl 3):22-34, 2001

• 24) 井上 猛, 小山 司:抗うつ薬の歴史と分類. 精神科薬物療法. 臨床精神医学講座 14, 中山書店, 東京, 1999, pp.109-121

• 25) Nelson JC, Mazure CM, Bowers MB Jr et al:A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307, 1991
  pubmed

• 26) Briley M:The logical evolution toward dual action antidepressants. Drugs in focus 3 (1), Adis Inernational, France, pp5-10, 2001

• 27) 上島国利:国内におけるMilnacipranの基礎と臨床. 臨床精神薬理 4:1177-1189, 2001

• 28) Lecrubier Y, Pletan Y, Solles A et al:Clinical efficacy of milnacipran:placebocontrolled trials. Int Clin Psychopharmacol 11 (Suppl 4):29-33, 1996

• 29) Ansseau M, von Frenckell R, Mertens C et al:Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 98:163-168, 1989
  pubmed

• 30) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin psychopharmacol 11 (Suppl 4):35-39, 1996

• 31) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997
  pubmed

• 32) Clerc et al. 2001, in press {Briley M:偶然性から論理性へ-抗うつ薬による治療の変遷-臨床精神薬理4:1163-1169, 2001より引用｝

• 33) Rouillon F, Warner B, Pezous N et al:Milnacipran efficacy in the prevention of recurrent depression:a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psycho-pharmacol 15:133-140, 2000

• 34) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価-塩酸イミプラミンを対照薬とした第III相臨床試験. 臨床医薬 11:819-842, 1995
  Medical*Online

• 35) 遠藤俊吉, 三浦貞則, 村崎光邦ほか:うつ病・うつ状態に対する新しい抗うつ薬塩酸ミルナシプランの臨床評価. 塩酸ミアンセリンを対照薬とした第III相臨床試験. Clin Eval 23:39-64, 1995

• 36) Blier P, de Montigny C:Current advances and trends in the treatment of depression. Trends Pharmacol Sci (TiPS) 15:220-226, 1994
  pubmed

• 37) 川勝 忍, 十束支朗, 吉村悦郎ほか:塩酸ミルナシプランの長期投与による有用性の検討. 臨床医薬 10:2715-2736, 1994
  Medical*Online

• 38) 高橋明比古, 村崎光邦, 稲見允昭ほか:新規抗うつ薬塩酸ミルナシプランの高齢者に対する臨床的有用性の検討. 臨床医薬 11 (Suppl 3):103-118, 1995

• 39) 村崎光邦:Milnacipranの基礎と臨床. 臨床精神薬理 3 (4):363-380, 2000

• 40) Stahl SM:Other neurotransmitter mechanism. Psychopharmacology of antidepressants. Martin Dunitz Ltd, London, 1997, pp61-82

• 41) Maj J, Rogoz Z:Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transm 106:197-211, 1999
  pubmed

• 42) 大坪天平, 上島国利:SNRIsの臨床応用. 臨床精神薬理 3:345-351, 2000

• 43) Gorman JM, Kent JM:SSRIs and SNRIs:Broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60 (Suppl 4):33-38, 1999

第2章 薬理編

P.29 掲載の参考文献

• 1) 小山 司:抗うつ薬の開発の歴史. 医薬ジャーナル 36:137-140, 2000

• 2) 井上 猛, 小山 司:抗うつ薬の歴史と分類. 臨床精神医学講座. 第14巻精神科薬物療法, 村崎光邦, 青葉安里編, 中山書店, 東京, 1999, pp. 109-121

• 3) 小山 司:感情障害の精神薬理学的研究. 精神薬療基金研究年報 30:48-53, 1997

• 4) Mochizuki D, Tsujita R, Yamada S et al:Neurochemical and behavioral characterization of milnacipran as a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (in press)

• 5) Wong DT, Bymaster FP, Mayle DA et al:LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23-33, 1993
  pubmed

• 6) Muth EA, Haskins JT, Moyer JA et al:Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986
  pubmed

• 7) 高橋義人, 小山 司:ラット前頭前野内側部細胞外モノアミン動態に及ぼすmilnacipran (TN-912) 急性投与の影響. 基礎と臨床 29:27-32, 1995
  Medical*Online

• 8) Kihara T, Ikeda M:Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272:177-183, 1995
  pubmed

• 9) Briley M:Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmac Clin Exp 13:99-111, 1998

• 10) 小山 司, 井上 猛:三環系・四環系抗うつ薬. 日本臨床 59:1513-1517, 2001
  Medical*Online

• 11) 小山 司, 傳田健三:強迫性障害の薬物療法. 臨床精神医学 22:1139-1147, 1993

• 12) 石金朋人, 小山 司, 松原繁廣ほか:新抗うつ薬fluvoxamine (SME-3110) の薬理特性:シナプス間隙モノアミン動態及び受容体に対する影響. 神経精神薬理16:37-43, 1994

• 13) Nelson JC, Mazure CM, Bowers MB Jr et al:A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307, 1991
  pubmed

• 14) 小山 司:抗うつ薬と脳内受容体. 臨床精神医学 16:1261-1275, 1987

• 15) 小山 司:SSRIの精神薬理特性-三環系抗うつ薬との比較を中心として. 脳と精神の医学 7:67-72, 1996

• 16) Moret C, Charveron M, Finberg Jp et al:Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219, 1985
  pubmed

• 17) Redmond DE Jr, Katz MM, Maas JW et al:Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic and healthy control subjects. Arch Gen Psychiatry 43:938-947, 1986
  pubmed

• 18) Inoue T, Tsuchiya K, Miura J et al:Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40:151-153, 1996
  pubmed

• 19) 小山 司, 石金朋人:三環系抗うつ薬, その他. 精神医学 36:17-21, 1994

• 20) 松原良次, 松原繁廣, 小山 司ほか:新抗うつ薬milnacipran (TN-912) 慢性投与によるラット大脳皮質β-adrenaline性受容体-adenylate cyclase系およびserotonin2受容体に対する影響. 神経精神薬理 15:119-126, 1993

• 21) Neliat G, Bodinier MC, Panconi E et al:Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 35:589-593, 1996

• 22) Nalepa I, Manier DH, Gillespie DD et al:Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 8:227-232, 1998

• 23) Rueter LE, De Montigny C, Blier P et al:Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 285:404-412, 1998
  pubmed

• 24) Mochizuki D, Hokonohara T, Kawasaki K et al:Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A autoreceptors but not postsynaptic 5-HT1A autoreceptors. J Psychopharmacology (in press)
  pubmed

• 25) Gardier AM, Malagie I, Trillat AC et al:Role of 5-HT1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs:recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10:16-27, 1996

• 26) Blier P, Pineyro G, el Mansari M et al:Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann NY Acad Sci 861:204-216, 1998
  pubmed

• 27) Artigas F, Romero L, Montigny C et al:Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonist. TINS19:378-383, 1997

• 28) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価-塩酸イミプラミンを対照薬とした第III相臨床試験-. 臨床医薬 11:819-842, 1995
  Medical*Online

• 29) 村崎光邦:SNRI開発の現状. 臨床精神薬理 1:419-430, 1998

• 30) Engleman EA, Robertson DW, Thompson DC et al:Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66:599-603, 1996
  pubmed

• 31) Moret C, Briley M:Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pighypothalamus. J Neurochem 69:815-822, 1997
  pubmed

• 32) Romero M, Bel N, Casanovas JM et al:Two actions are better than one:avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors. Int Clin Psychopharmacol 11 (Suppl 4):1-8, 1996

• 33) Leonard BE:Neuropharmacology of antidepressants that modify central noradrenergic and serotonergic function:A short review. Hum Psychopharmacol Clin Exp 14:75-81, 1999

• 34) Cleare AJ, Murray RM, O'Keane V:Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology 134:406-410, 1997
  pubmed

• 35) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 36) Holliday SM, Benfield P:Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294, 1995
  pubmed

• 37) 塩野義製薬株式会社社内資料

P.44 掲載の参考文献

• 1) Artigas F, Romero L, de Montigny C et al:Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-383, 1996

• 2) Assie MB, Charveron M, Palmier C et al:Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 31:149-155, 1992
  pubmed

• 3) Beique J, de Montigny C, Blier P et al:Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine:I. in vivo electrophysiological studies in the rat. Neuropharmacology 39:1800-1812, 2000
  pubmed

• 4) Beique J, de Montigny C, Blier P et al:Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine:II. in vitro studies in the rat. Neuropharmacology 39:1813-1822, 2000

• 5) Bel N, Artigas F:Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245, 1993

• 6) Bel N, Artigas F:Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran, microdialysis studies in rats. Neuropsychopharmacology 21:745-754, 1999
  pubmed

• 7) Blier P, Bergeron R, de Montigny C:Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 16:333-338, 1997
  pubmed

• 8) Blier P, de Montigny C:Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226, 1994
  pubmed

• 9) Briley M:Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Human Psychopharmacol 13:99-111, 1998

• 10) Carboni E, Tanda GL, Frau R et al:Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex:evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070, 1990
  pubmed

• 11) Dawson LA, Nguyen HQ,Geiger A:Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex:augmentation via 5-HT1A receptor antagonism. Neuropharmacology 38:1153-1163, 1999
  pubmed

• 12) Duman RS, Heninger GR, Nestler EJ:A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606, 1997
  pubmed

• 13) Frazer A:Pharmacology of antidepressants. J Clin Psychopharmacol 17 (Suppl 1):S2-S18, 1997

• 14) Gartside SE, Umbers V, Sharp T:Inhibition of 5-HT cell firing in the DRN by nonselective 5-HT reuptake inhibitors:studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms. Psychopharmacology 130:261-268, 1997
  pubmed

• 15) Hjorth S, Bengtsson HJ, Milano S et al:Studies on the role of 5-HT1A autoreceptors and α1-adrenoceptors in the inhibition of 5-HT release-I. BMY7378 and prazosin. Neuropharmacology 34:615-620, 1995

• 16) Huang YH, Maas JW, Hu GH:The time course of noradrenergic pre- and postsynaptic activity during chronic desipramine treatment. Eur J Pharmacol 68:41-47, 1980
  pubmed

• 17) Invernizzi R, Bramante M, Samanin R:Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output:role of presynaptic 5-HT1A receptors. Eur J Pharmacol 260:243-246, 1994
  pubmed

• 18) Kihara T, Ikeda M:Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272:177-183, 1995
  pubmed

• 19) 北村佳久, 長谷忠, 高尾勝幸ほか:新規抗うつ薬Milnacipranの薬理学的作用の検討. 神経精神薬理17:25-34, 1995

• 20) Lacroix D, Blier P, Curet O et al:Effects of long-term desipramine administration on noradrenergic neurotransmission:electro-physiological studies in the rat brain. J Pharmacol Exp Ther 257:1081-1090, 1991

• 21) Maj J, Dziedzicka-Wasylewska M, Rogoz R et al:Effects of venlafaxine given repeatedly on α1- adrenergic, dopaminergic and serotonergic receptors in rat brain. Human Psychopharmacol 14:333-344, 1999

• 22) Maj J, Rogoz Z:Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly on the α1-adrenergic, dopamine and serotonin systems. J Neural Transm 106:197-211, 1999

• 23) Maj J, Rogoz Z, Dlaboga D et al:Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the α1-adrenergic and serotonergic 5-HT2A systems. J Neural Transm 107:1345-1359, 2000

• 24) 松原良次, 松原繁廣, 小山司ほか:新抗うつ薬milnacipran (TN-912) 慢性投与によるラット大脳皮質β-adrenaline性受容体-adenylate cyclase系およびserotonin2受容体に対する影響. 神経精神薬理15:119-126, 1993

• 25) Middlemiss DN:The putative 5-HT1 receptor agonist, RU24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. J Pharm Pharmacol 37:434-437, 1985

• 26) Millan MJ, Lejeune F, Gobert A:Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex:relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138, 2000

• 27) Mongeau R, de Montigny C, Blier P:Electrophysiologic evidence for desensitization of α2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10:41-51, 1994

• 28) Mongeau R, Weiss M, de Montigny C et al:Effect of acute, short-and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 37:905-918, 1998

• 29) Moret C, Briley M:Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 180:351-356, 1990
  pubmed

• 30) Moret C, Briley M:Effect of milnacipran and desipramine on noradrenergic α2-autoreceptor sensitivity. Prog Neuropsychopaharmacol Biol Psychiatry 18:1063-1072, 1994

• 31) Moret C, Briley M:Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 69:815-822, 1997
  pubmed

• 32) Nalepa I, Manier DH, Gillespie DD et al:Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 8:227-232, 1998

• 33) Neliat G, Bodinier MC, Panconi E et al:Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 35:589-593, 1996

• 34) Nibuya M, Nestler EJ, Duman RS:Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372, 1996
  pubmed

• 35) Popoli M, Vocaturo C, Perez J et al:Presynaptic Ca2+/calmodulin-dependent protein kinase II:autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Mol Pharmacol 48:623-629, 1995
  pubmed

• 36) Price GW, Roberts C, Watson J et al:Species differences in 5-HT autoreceptors. Behav Brain Res 73:79-82, 1996
  pubmed

• 37) Rossby SP, Manier DH, Liang S et al:Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int J Neuropsychopharmacol 2:1-8, 1999
  pubmed

• 38) Rueter LE, Kasamo K, de Montigny C et al:Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmidebergs Arch Pharmacol 357:600-610, 1998
  pubmed

• 39) Sakaue M, Somboonthum P, Nishihara B et al:Postsynaptic 5-hydroxytryptamine 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129:1028-1034, 2000
  pubmed

• 40) Scuvee-Moreau JJ, Dresse AE:Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur J Pharmacol 57:219-225, 1979
  pubmed

• 41) Sharp T, Bramwell SR, Grahame-Smith DG:5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96:283-290, 1989
  pubmed

• 42) Stanford SC:Prozac:panacea or puzzle? Trends Pharmacol Sci 17:150-154, 1996
  pubmed

• 43) Suzuki M, Matsuda T, Asano S et al:Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine 1A receptor activation. Br J Pharmacol 115:703-711, 1995
  pubmed

• 44) Vetulani J, Nalepa I:Antidepressants:past, present and future. Eur J Pharmacol 405:351-363, 2000
  pubmed

• 45) Watanabe M, Kodama Y, Hagino Y et al:Effect of chronic amitriptyline administration on serotonergic receptors in rats with methylazoxymethanol-induced microencephaly. Brain Res 787:333-336, 1998
  pubmed

• 46) Yoshioka M, Matsumoto M, Numazawa R et al:Changes in the regulation of 5-hydroxytryptamine release by α2-adrenoceptors in the rat hippocampus after long-term desipramine treatment. Eur J Pharmacol 294:565-570, 1995

P.57 掲載の参考文献

• 1) Musselman DL, Evans DL, Nemeroff CB:The relationship of depression to cardiovascular disease:epidemiology, biology, and treatment. Arch Gen Psychiatry 55:580-592, 1998
  pubmed

• 2) Schulz R, Beach SR, Ives DG et al:Association between depression and mortality in older adults:the Cardiovascular Health Study. Arch Intern Med 160:1761-1768, 2000
  pubmed

• 3) Michelson D, Stratakis C, Hill L et al:Bone mineral density in women with depression. N Engl J Med 335:1176-1181, 1996
  pubmed

• 4) Ciechanowski PS, Katon WJ, Russo JE:Depression and diabetes:impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 160:3278-3285, 2000
  pubmed

• 5) Murray CJ, Lopez AD:Global mortality, disability, and the contribution of risk factors:Global Burden of Disease Study. Lancet 349, 1436-1442, 1997
  pubmed

• 6) Mesulam MM:Neuroplasticity failure in Alzheimer's disease:bridging the gap between plaques and tangles. Neuron 24:521-529, 1999
  pubmed

• 7) Charney DS:Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 59:11-14, 1998
  pubmed

• 8) Manji HK, Lenox RH:Signaling:cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48:518-530, 2000
  pubmed

• 9) Manji HK, Moore GJ, Rajkowska G et al:Neuroplasticity and cellular resilience in mood disorders. Millennium article. Mol Psychiatry 5:578-593, 2000

• 10) Bourne HR, Nicoll R:Molecular machines integrate coincident synaptic signals. Cell 72 65-75, 1993
  pubmed

• 11) Bhalla US, Iyengar R:Emergent properties of networks of biological signaling pathways. Science 283:381-387, 1999
  pubmed

• 12) McEwen BS:Stress and hippocampal plasticity. Annu Rev Neurosci 22:105-122, 1999
  pubmed

• 13) Sapolsky RM:Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925-935, 2000
  pubmed

• 14) Drevets WC:Neuroimaging studies of mood disorders:Implications for a neural model of major depression. Biol Psychiatry 48:813- 829, 2000

• 15) Steffens DC, Tupler LA, Ranga K et al:Magnetic resonance imaging signal hypointensity and iron content of putamen nuclei in elderly depressed patients. Psychiatry Res 83:95-103, 1998
  pubmed

• 16) Black IB:Trophic regulation of synaptic plasticity. J Neurobiol 41:108-118, 1999
  pubmed

• 17) Riccio A, Ahn S, Davenport CM et al:Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286:2358-2361, 1999
  pubmed

• 18) Adams JM, Cory S:The Bcl-2 protein family:arbiters of cell survival. Science 281:1322-1326, 1998
  pubmed

• 19) Chen DF, Schneider GE, Martinou JC et al:Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 385:434-439, 1997
  pubmed

• 20) Manji HK et al:Regulation of signal transduction pathways by mood stabilizing agents:Implications for the pathophysiology and treatment of bipolar affective disorder. In Bipolar Medications:Mechanisms of action. (eds. Manji HK, Bowden CL, Belmaker RH) 129-177 (American Psychiatric Press, Washington DC, 2000)

• 21) Chen G, Zeng WZ, Yuan PX et al:The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 272:879-882, 1999

• 22) Chen RW, Chuang DM:Long term lithium treatment suppresses p53 and Bax expression but increases bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274:6039-6042, 1999
  pubmed

• 23) Klein PS, Melton DA:A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455-8459, 1996
  pubmed

• 24) Tsai G, Coyle JT:N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46:531-540, 1995
  pubmed

• 25) Bates TE, Strangward M, Keelan J et al:Inhibition of N-acetylaspartate production:implications for 1H MRS studies in vivo. Neuroreport 7:1397-1400, 1996

• 26) Moore GJ, Bebchuk JM, Hasanat K et al:Lithium increases N-acetyl-asparate in the human brain:in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48:1-8, 2000

• 27) Maeda H, Ozawa H, Saito T et al:Potential antidepressant properties of forskolin and a novel water-soluble forskolin (NKH477) in the forced swimming test. Life Sci 61:2435-2442, 1997

• 28) Baldessarini RJ:In Goodman & Gilman's. The pharmacological basis of the therapeutics, McGrawe-Hills:New York, 1996

• 29) Pacher P, Ungvari Z, Nanasi PP et al:Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 6:469-480, 1999
  pubmed

• 30) Glassman AH:Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 35:503-511, 1984
  pubmed

• 31) Leonard B-E, Healy D:Differential Effects of Antidepressants, Martin Dunitz:London, 1999

• 32) Wong DT, Bymaster FP, Reid LR et al:Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32:1287-1293, 1983
  pubmed

• 33) Wong DT, Bymaster FP, Engleman EA:Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug:twenty years since its first publication. Life Sci 57:411-441, 1995

• 34) Wong DT, Bymaster FP:Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv Exp Med Biol 363:77-95, 1995
  pubmed

• 35) Caccia S:Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302, 1998
  pubmed

• 36) Muth EA, Haskins JT, Moyer JA et al:Antidepressant biochemical profile of the novel bicycliccompound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986
  pubmed

• 37) Caille D, Bergis OE, Fankhauser C et al:Befloxatone, a new reversible and selective monoamine oxidase- A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277:265-277, 1996
  pubmed

• 38) Rosenzweig P, Patat A, Curet O et al:Clinical pharmacology of befloxatone:a brief review. J Affect Disord 51:305-312, 1998
  pubmed

• 39) Arborelius L, Owens MJ, Plotsky PM et al:The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12, 1999
  pubmed

• 40) Timpl P, Spanagel R, Sillaber I et al:Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1110ee comments. Nat Genet 19:162-166, 1998

• 41) Smith GW, Aubry JM, Dellu F et al:Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102, 1998
  pubmed

• 42) Owens MJ, Nemeroff CB:Corticotropin-releasing factor antagonists in affective disorders. Expert Opin Investig Drugs 8:1849-1858, 1999
  pubmed

• 43) Mansbach RS, Brooks EN, Chen YL:Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 1323:21-26, 1997

P.72 掲載の参考文献

• 1) Kent JM:SNaRIs, NaSSAs, and NaRIs:new agents for the treatment of depression Lancet 355:911-918, 2000
  pubmed

• 2) Patat A, Troy S, Burke J et al:Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. J Clin Pharmacol 38:256-267, 1998
  pubmed

• 3) Taft DR, Iyer GR, Behar L et al:Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. Drug Metab Dispos 25:1215-1218, 1997
  pubmed

• 4) Troy SM, Parker VP, Hicks DR et al:Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J Clin Pharmacol 37:954-961, 1997
  pubmed

• 5) Otton SV, Ball SE, Cheung SW et al:Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149-156, 1996
  pubmed

• 6) Fogelman SM, Schmider J, Venkatakrishnan K et al:O-and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells:effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480-490, 1999

• 7) 福田剛史, 東 純一:CYP2D6*10の代謝特性に関するin vitro, in vivoでの検討. 薬物動態 15:165-170, 2000

• 8) Fukuda T, Nishida Y, Zhou Q et al:The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56:175-180, 2000

• 9) 福田剛史, 東 純一:CYP2D と遺伝子多型. 月刊薬事43 (2月臨時増刊号):466-472, 2001

• 10) Ilett KF, Hackett LP, Dusci LJ et al:Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 45:459-462, 1998

• 11) Schweizer E, Weise C, Clary C et al:Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 11:233-236, 1991
  pubmed

• 12) Caccia S:Metabolism of the newer antidepressants:An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302, 1998
  pubmed

• 13) Troy SM, Schultz RW, Parker VD et al:The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 56:14-21, 1994
  pubmed

• 14) Klamerus KJ, Parker VD, Rudolph RL et al:Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmakokinetics. Pharmacotherapy 16:915-923, 1996

• 15) Spencer CM, Wilde MI:Milnacipran:A review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 16) 酒井敦史, 望月紀子, 杉原太助ほか:新規抗うつ薬ミルナシプランの体内動態 (第1報) ラットにおける吸収, 分布, 代謝および排泄. 基礎と臨床 28:3649-3670, 1994
  Medical*Online

• 17) Puozzo C, Filaquier C, Briley M:Plasma level of F2207, milnacipran, a novel antidepressant, after single oral administration in volunteers (abstract). Br J Clin Pharmacol 20:p291, 1985

• 18) Retz W, Becker T, Schmidtke A et al:Multiple and single dose pharmacokinetics of milnaciplan in major depressive patients (abstract). Eur Neuropsychopharmacol 5:296-297, 1995

• 19) 高橋明比古, 川口 毅, 笠原友幸ほか:塩酸ミルナシプラン15mg錠の健常人による吸収排泄試験:食事の及ぼす影響並びに反復投与による薬物動態の検討. 臨床医薬 11 (Suppl 3):119-132, 1995

• 20) 中道 昇, 関野久之, 及村昌臣ほか:高齢者における塩酸ミルナシプランの薬物動態の検討. 臨床医薬 11 (Suppl 3):133-143, 1995

• 21) 村崎光邦, 三浦貞則, 山下 格ほか:うつ病, うつ状態に対する新規抗うつ薬塩酸ミルナシプラン (TN-912) の臨床評価. 臨床医薬 11 (Suppl 3):71-83, 1995

• 22) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価:塩酸イミプラミンを対照薬とした第III相臨床試験. 臨床医薬 11:819-842, 1995
  Medical*Online

• 23) Puozzo C, Filaquier C, Briley M:Pharmacokinetic-pharmacodynamic relationship of milnacipran in platelet uptake model (abstract). Eur Neuropsychopharmacology 6 (Suppl 1):S17, 1996

• 24) Puozzo C, Lambe R, Filaquier C:Plasma level and (2H)-5HT uptake in platelets after human repeated administration of milnacipran (abstract). Acta Pharmacol Toxicol 59:214, 1986

• 25) Puozzo C, Albin H, Vincon G et al:Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 23:273-279, 1998
  pubmed

• 26) Puozzo C, Pozet N, Deprez D et al:Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet 23:280-286, 1998
  pubmed

• 27) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 28) Sharma A, Goldberg MJ, Cerimele BJ:Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161-167, 2000
  pubmed

• 29) Berk M, du Plessis AD, Birkett M et al:An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Int Clin Psychopharmacol 12:137-140, 1997

• 30) Turcotte JE, Debonnel G, de Montigny C et al:Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24:511-521, 2001
  pubmed

• 31) Crismon ML, Trivedi M, Pigott TA et al:The Texas Medication Algorithm Project:report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60:142-156, 1999
  pubmed

• 32) Anonymous:Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157 (Suppl 4):1-45, 2000

第3章 治療編

P.87 掲載の参考文献

• 1) Briley M:Understanding antidepressants. Martin-Dunitz, London, pp25-45, 2000

• 2) Delgado P, Moreno F:Antidepressants and the brain. Int Clin Psychopahmacol 14 (Suppl 1):S9-S16, 1999

• 3) Leonard BE, Healy D:Differential effects of antidepressants. Martin-Dunits, London, pp25-45, 2000

• 4) 松原良次, 松原繁廣, 小山 司ほか:新抗うつ薬milnacipran (TN912) 慢性投与によるラット大脳皮質β adrenaline性受容体adenylate cyclase系およびserotonin2受容体に対する影響. 神経精神薬理 15:119-126, 1993

• 5) Mochizuki D, Hokonohara T, Kawasaki K et al:Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A autoreceptors but not postsynaptic 5-HT1A receptors. 旭化成社内資料, 2002

• 6) Parker G, Roy K, Wilhelm K et al:Assessing the comparative effectiveness of antidepressant therapies:a prospective clinical practice study. J Clin Psychiatry 62:117-123, 2001
  pubmed

• 7) Vogel G:Neuroscience. New brain cells prompt new theory of depression. Science 290 (5490):258-259, 2000
  pubmed

P.94 掲載の参考文献

• 1) Anderson IM:SSRIS versus tricyclic antidepressants in depressed inpatients:a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl 1):11-17, 1998

• 2) Ansseau M, Papart P, Troisfontaines B et al:Controlled comparison of milnacipran and fluoxetine in major depression. Psycopharmacology (Berl) 114:131-137, 1994

• 3) Ansseau M, von Frenckell R, Mertens C et al:Controlled comparison of two doses of milnacipran (F2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 98:163-168, 1989
  pubmed

• 4) Ansseau M, von Frenckell R, Papart P et al:Controlled comparison of milnacipran (F2207) 200mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 4:221-227, 1989

• 5) Benedictis E:Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 14:61-66, 2000
  pubmed

• 6) Bowden CL, Schatzberg AF, Rosenbaum A et al:Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 13:305-311, 1993
  pubmed

• 7) Briley M:Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacology 13:99-111, 1998

• 8) Burnett FE:The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 9:303-320, 1998

• 9) Clerc GE, Ruimy P, Verdeau-Pailles J:on behalf of the Venlafaxine French Inpatient Study Group:A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Psychopharmacol 9:139-143, 1994

• 10) Clerc G, Milnacipran/Fluvoxamine Study Group:Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibotor:a comparison with fluvoxamine. Int Clin Psychoa pharmacol 16:145-151, 2001

• 11) Cohn CK, Shrivastava R, Mendels J et al:Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 51 (Suppl B):28-33, 1990

• 12) Cole J, Schatzberg A, Sniffin C et al:Trazodone in treatment of resistant depression:an open study. J Clin Psychopharmacol 1 (Suppl):S49-S54, 1981

• 13) Danish University Antidepressant Group:Citalopram:clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 90:131-138, 1986
  pubmed

• 14) Danish University Antidepressant Group:Paroxetine:a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study.J Affect Disord 18:289-299, 1990

• 15) Dierick M, Ravizza L, Realini R et al:A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatr 20:57-71, 1996

• 16) Einarson TR, Arikian SR, Casciano J et al:Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression:a meta-analysis of randomized controlled trial. Clin Ther 21:296-308, 1999
  pubmed

• 17) Feighner JP:The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 55 (Suppl A):62-68, 1994

• 18) Guelfi JD, White C, Hackett D et al:Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-458, 1995
  pubmed

• 19) 石郷岡純, 岩尾光浩:SNRIの臨床効果. 医薬ジャーナル36:728-734, 2000

• 20) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39, 1996

• 21) Lecrubier Y, Pletan Y, Solles A et al:Clinical efficacy of milnacipran:placebocontrolled trials. Int Clin Psychopharmacol 11 (Suppl 4):29-33, 1996

• 22) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (1Suppl 4):41-46, 1996

• 23) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価─塩酸イミプラミンを対照薬とした第III相臨床試験─. 臨床医薬 11 (4):819-842, 1995
  Medical*Online

• 24) McPartlin GM, Reynolds A, Anderson C et al:A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 4:127-132, 1998

• 25) Mehtonen OP, Sogaard J, Roponen P et al:Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61:95-100, 2000
  pubmed

• 26) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran:an overview. Int Clin Psychopharmacol 11 (Suppl 4):47-51, 1996

• 27) 村崎光邦:Milnacipranの基礎と臨床. 臨床精神薬理 3:363-380, 2000

• 28) Ottevanger EA:The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 18:731-740, 1994
  pubmed

• 29) Poirier MF, Boyer P:Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison. Br J Psychiatry 175:12-16, 1999
  pubmed

• 30) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997
  pubmed

• 31) Roose SP, Glassman AH, Attia E et al:Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151:1735-1739, 1994
  pubmed

• 32) Rudolph RL, Derivan AT, for the Venlafaxine XR 211 Study Group:Double-blind, placebo-controlled study of once-daily venlafaxine XR and fluoxetine in depressed outpatients. In:Scientific Abstracts in the 36th Annual Meeting of the American College of Neuropsychiatry, December 8-12, 1997, Waikoloa, Hawaii

• 33) Rudolph RL, Feiger AD:A double-blind, randomized, placebo-controlled trial of once daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171-181, 1999
  pubmed

• 34) Schatzberg AF:Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 60 (Suppl 4):14-21, 1999

• 35) Schweizer E, Feighner J, Mandos LA et al:Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55:104-108, 1994
  pubmed

• 36) Shrivastava RK, Cohn C, Crowder J et al:Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14:322-329, 1994
  pubmed

• 37) Song F, Freemantle N, Sheldon TA et al:Selective serotonin reuptake inhibitors:meta-analysis of efficacy and acceptability. Br Med J 306:683-687, 1993

• 38) Spencer CM, Wilde MI:Milnacipran:A review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 39) Stuppaeck CH, Geretsegger C, Whitworth AB et al:A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 14:241-246, 1994
  pubmed

• 40) Tignol J, Pujol-Domenech J, Chartres JP et al:Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 97:157-165, 1998
  pubmed

• 41) Tylee A, Beaumont G, Bowden M et al:A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry 3:51-58, 1997

• 42) Tzanakaki M, Guazzelli M, Nimatoudis I et al:Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Intl Psychopharmacol 15:29-34, 2000

• 43) Wheadon D:Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology;December 1993, Honolulu, Hawaii

P.106 掲載の参考文献

• 1) Macher JP, Sichel Jp, Serre C et al:Double-blind placebo- controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82, 1989
  pubmed

• 2) Lecrubier Y, Pletan Y, Solles A et al:Clinical efficacy of milnacipran:Placebo- controlled trials. Int Clin Psychopharmacol 11 (Suppl 4):29-33, 1996

• 3) Peuch A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and nor-adrenaline reuptake inhibitor:An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997

• 4) Ansseau M, von Frenckell R, Mertens C et al:Controlled comparison of two doses of milnacipran (F2207) and amitriptyline in major depressive inpatients. Psychopharmacology 98:163-168, 1989
  pubmed

• 5) Ansseau M, von Frenckell R, Papart P et al:Controlled comparison of milnacipran (F 2207) 200mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 4:221-227, 1989

• 6) Leinonen E, Lepola U, Koponen H et al:Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 96:497-504, 1997
  pubmed

• 7) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:A summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39, 1996

• 8) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran:An overview. Int Clin Psychopharmacol 11 (Suppl 4):47-51, 1996

• 9) Ansseau M, Papart P, Troisfontaines B et al:Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 114:131-137, 1994
  pubmed

• 10) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4):41-46, 1996

• 11) Clerc G and the Milnacipran/Fluvoxamine Study Group:Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor:A comparison with fluvoxamine. Int Clin Psychopharmacol 16:145-151, 2001

• 12) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価塩酸イミプラミンを対照薬とした第III相臨床試験─. 臨床医薬 11:819-842, 1995

• 13) 遠藤俊吉, 三浦貞則, 村崎光邦ほか:うつ病・うつ状態に対する新しい抗うつ薬塩酸ミルナシプランの臨床評価塩酸ミアンセリンを対照薬とした第III相臨床試験─. 臨床評価 23:39-64, 1995

• 14) 村崎光邦, 森 温理, 山下 格ほか:選択的セロトニン再取り込み阻害薬SME3110 (fluvoxamine maleate) のうつ病およびうつ状態に対する臨床後期第II相試験─塩酸イミプラミンを対照とした用量範囲の検討─. 臨床医薬 14:919-949, 1998
  Medical*Online

• 15) 三浦貞則, 山下 格, 浅井昌弘ほか:選択的セロトニン再取り込み阻害薬塩酸パロキセチンのうつ病およびうつ状態に対する臨床評価─塩酸イミプラミンを対照とした用量設定試験─. 薬理と治療 28 (Suppl 1):137-160, 2000

• 16) Guelfi JD, White C, Hackett D et al:Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Clin Psychiatry 56:450-458, 1995
  pubmed

• 17) Burnett FE, Dinan TG:The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 9:303-320, 1998

• 18) Rudolph RL Fabre LF, Feighner JP et al:A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122, 1998
  pubmed

• 19) Montgomery SA:Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 10 (Suppl 2):21-27, 1995

• 20) Benkert O, Grunder G, Wetzel H et al:A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia. J Psychiat Res 30:441-451, 1996
  pubmed

• 21) Schweizer E, Feighner J, Mandos LA et al:Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psyhiatry 55:104-108, 1994

• 22) Samuelian JC, Hackett D:A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression.J Psychopharma-cology 12:273-278, 1998

• 23) Gentil V, Kerr-Correa F, Moreno R et al:Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacology 14:61-66, 2000
  pubmed

• 24) Clerc GE, Ruimy P, Verdeau-Pailles J et al:A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9:139-143, 1994

• 25) Costa e Silva J:Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59:352-357, 1998
  pubmed

• 26) Rudolph RL, Feiger AD:A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171-181, 1999
  pubmed

• 27) Ballus C, Quiros G, de Flores T et al:The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 15:43-48, 2000
  pubmed

• 28) Mehtonen OP, Sogaard J, Roponen P et al:Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61:95-100, 2000
  pubmed

• 29) Thase ME, Entsuah AR, Rudolph RL:Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241, 2001
  pubmed

• 30) Cunningham LA for the Venlafaxine XR 208 Study Group:Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 9:157-164, 1997

• 31) 和田雄治:SNRI系抗うつ・尿失禁治療薬塩酸デュロキセチン. 脳の科学 20:921-926, 1998

• 32) Leon AC:Measuring onset of antidepressant action in clinical trials:An overview of definitions and methodology. J Clin Psychiatry 62 (Suppl 4):12-16, 2001

• 33) Thase ME:Methodology to measure onset of action. J Clin Psychiatry 62 (Suppl 15):18-21, 2001

• 34) Khan A, Fabre LF, Rudolph R:Venlafaxine in depressed outpatients. Psychopharmacol Bull 27:141-144, 1991
  pubmed

• 35) Schweizer E, Weise C, Clary C et al:Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 11:233-236, 1991
  pubmed

• 36) Schrivastava R, Patrick R, Scherer N et al:A dose-response study of venlafaxine. Neuropsychopharmacology 10 (Suppl 3):221, 1994

• 37) Derivan A, Entsuah AR, Kikta D:Venlafaxine:Measuring the onset of anti-depressant action. Psychopharmacol Bull 31:439-447, 1995

• 38) 松原繁廣:β-受容体. 感情障害-基礎と臨床, 笠原 嘉, 松下正明, 岸本英爾編, 朝倉書店, 東京, 1997, pp.243-252

• 39) 松原良次, 松原繁廣, 小山 司:SNRIの薬効・薬理. 臨床精神薬理 3:325-330, 2000

• 40) Moret C, Charveron M, Finberg JPM et al:Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219, 1985

• 41) 松原良次, 松原繁廣, 小山 司ほか:新抗うつ薬milnacipran (TN-912) 慢性投与によるラット大脳皮質β-adrenaline性受容体-adenylate cyclase系およびserotoin2受容体に対する影響. 神経精神薬理 15:119-126, 1993

• 42) Yardley JP, Husbands GEM, Stack G et al:2-Phenyl-2- (1-hydroxycycloalkyl) ethylamine derivatives:Synthesis and antidepressant activity. J Med Chem 33:2899-2905, 1990

• 43) Nalepa I, Manier DH, Gillespie DD et al:Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 8:227-232, 1998

• 44) Rossby SP, Sulser F:Antidepressants and post-receptor events:The 'serotonin/ norepinephrine link' revisited. Antidepressant therapy:At the dawn of the third millennium, ed. by Briley M, Montgomery SA, Martin Dunitz, London, 1998, pp. 69-86

• 45) Blier P, de Montigny C:Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226, 1994
  pubmed

• 46) Artigas F, Perez V, Alvarez E et al:Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:248-251, 1994
  pubmed

• 47) Dawson LA, Nguyen HQ, Geiger A:Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex:Augmentation via 5-HT1A receptor antagonism. Neuropharmacology 38:1153- 1163, 1999

• 48) Moret C, Briley M:Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 69:815-822, 1997
  pubmed

• 49) 望月大介:SNRIの抗うつ作用発現メカニズム. 医薬ジャーナル 36:721-727, 2000

• 50) Blier P:Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62 (Suppl 15):12-17, 2001

• 51) Nelson JC, Mazure CM, Bowers MB et al:A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307, 1991
  pubmed

• 52) Muth EA, Haskins JT, Moyer JA et al:Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986
  pubmed

• 53) Muth EA, Moyer JA, Haskins JT et al:Biochemical, neurophysiological, and behavioral effects of Wy-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199, 1991

• 54) Harvey AT, Rudolph RL, Preskorn SH:Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509, 2000
  pubmed

P.117 掲載の参考文献

• 1) 田所千代子, 上島国利:うつ病の再燃・再発の実態. 精神科治療学 15:3-11, 2000

• 2) 樋口輝彦:難治性うつ病の臨床. 感情障害全般の治療から難治性への対処まで, 診療新社, 大阪, 1997, pp 1-67

• 3) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, 4th edition. APA, Washington, D. C., 1994, pp317-391

• 4) Depression Guideline Panel (DGP):Depression in primary care, volume 2 Treatment of major depression. US Department of Health and Human Services, Public Health service Agency for Health Care Policy and Research, Rockville, 1993, pp 1-175

• 5) Lee AS, Murray RM:The long-term outcome of Maudsley depressives. Br J Psychiatry 153:741-751, 1988

• 6) Maj M, Veltro F, Pirozzi R et al:Pattern of recurrence of illness after recovery from an episode of major depression:a prospective study. Am J Psychiatry 149:795-800, 1992
  pubmed

• 7) Surtees PG, Barkley C:Future imperfect:the long-term outcome of depression. Br J Psychiatry 164:327-341, 1994

• 8) Paykel ES, Priest RG:Recognition and management of depression in general Practice:consensus statement. BMJ 305:1198-1202, 1992
  pubmed

• 9) 五十川浩一, 山本由起子, 穐吉條太郎:抗うつ薬とリチウム併用にクロナゼパムの付加投与が有効であった遷延性うつ病の1症例. 臨床精神医学 26:1545-1549, 1997
  Medical*Online

• 10) 佐々木一郎:Augmentation therapyが有効であったdouble depressionの2症例. 臨床精神医学 27:1131-1137, 1998
  Medical*Online

• 11) 葛城里美, 佐々木一郎, 土山幸之助ほか:抗うつ薬とメチルフェニデートの併用が有効であった難治性うつ病の2症例. 精神医学 38:1236-1237, 1996

• 12) 山本由起子, 五十川浩一, 穐吉條太郎ほか:大うつ病性障害における抗うつ薬治療抵抗化因子. 精神医学 39:1083-1087, 1997

• 13) 永山治男:高照度光療法. -うつ病治療の最前線-うつ病治療の展開. こころの科学 97:82-85, 2001

• 14) 松原良次, 松原繁廣, 小山 司:SNRIの薬効・薬理. 臨床精神薬理 3:325-330, 2000

• 15) 三浦貞則:SNRIの登場とその歴史的背景. 臨床精神薬理 3:311-318, 2000

• 16) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 17) 村崎光邦:SNRI開発の現状. 臨床精神薬理 1:419-430, 1998

• 18) Eguchi J, Inomata Y, Yuasa T et al:Pharmacological profile of the novel antidepressant 4- (2-fluorophenyl)-6- methyl-2- (1 piperazinyl) thieno-[2, 3-d] pyrimidine monohydrate hydrochloride. Arzneimittelforschung 47:1337-1347, 1997
  pubmed

• 19) Kupfer DJ:Long-term treatment of depression. J Clin Psychiatry 52 (Suppl):28-34, 1991

• 20) Janicak PG, Davis JM, Preskorn SH et al:Principles and Practice of Psychopharmacotherapy. Williams & Wilkins, Baltimore, 1993

• 21) Guelfi JD, White C, Hackett D et al:Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-458, 1995
  pubmed

• 22) Lecrubier Y, Pletan Y, Solles A et al:Clinical efficacy of milnacipran:placebo-controlled trials. Int Clin Psychopharmacol 11 (Suppl 4):29-33, 1996

• 23) Schweizer E, Feighner J, Mandos LA et al:Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55:104-108, 1994
  pubmed

• 24) Rudolph RL, Fabre LF, Feighner JP et al:A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122, 1998
  pubmed

• 25) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39, 1996

• 26) Prien RF, Kupfer DJ:Continuation drug therapy for major depressive episodes:how long should it be maintained? Am J Psychiatry 143:18-23, 1986
  pubmed

• 27) Seager CP, Bird RL:Imipramine with electrical treatment in depression- a controlled trial. J Ment Sci 108:704-707, 1962

• 28) Mindham RH, Howland C, Shepherd M:An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 3:5-17, 1973
  pubmed

• 29) Prien RF, Klett CJ, Caffey EM Jr:Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 29:420- 425, 1973

• 30) Klerman GL, Dimascio A, Weissman M et al:Treatment of depression by drugs and psychotherapy.Am J Psychiatry 131:186-191, 1974
  pubmed

• 31) Coppen A, Ghose K, Montgomery S et al:Continuation therapy with amitriptyline in depression. Br J Psychiatry 133:28-33, 1978
  pubmed

• 32) Stein MK, Rickels K, Weise CC:Maintenance therapy with amitriptyline:a controlled trial. Am J Psychiatry 137:370-371, 1980
  pubmed

• 33) WHO Mental Health Collaborating Centres:Pharmacotherapy of depressive disorders. A consensus statement. J Affect Disord 17:197-198, 1989
  pubmed

• 34) Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP):Impact of neuropharmacology in the 1990s-strategies for the therapy of depressive illness. Eur Neuropsychophrmacol 3:153-156, 1993
  pubmed

• 35) American Psychiatric Association (APA):Practice guideline for major depressive disorder in adults. Am J Psychiatry 150 (Supp14):1-26, 1993

• 36) 古川壽亮:エビデンス精神科医療. 実証的証拠に基づく精神疾患の治療指針, I気分・不安・人格の障害, 大塚俊男, 風祭 元, 北村俊則ほか, 日本評論社, 東京, 1998, pp. 17-29

• 37) British Association for Psychopharmacology (BAP):Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 7:19-23, 1993

• 38) Thase ME, Kupfer DJ:Recent developments in the pharmacology of mood disorders. J Consult Clin Psychol 64:646-659, 1996

• 39) Entsuah AR, Rudolph RL, Hackett D et al:Efficacy of venlafaxine and placebo during long-term treatment of depression:a pooled analysis of relapse rates. Int Clin Psychopharmacol 11:137-145, 1996
  pubmed

• 40) Thase ME:Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 60 (Suppl 6):15-19, 1999

• 41) Rouillon F, Warner B, Pezous N et al:Milnacipran efficacy in the prevention of recurrent depression:a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol 15:133-140, 2000

• 42) NIMH/NIH Consensus Development Conference statement. Mood disorders:pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry 142:469-476, 1985
  pubmed

• 43) Montgomery SA, Dufour H, Brion S et al:The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry (Suppl) 3:69-76, 1988
  pubmed

• 44) Frank E, Kupfer DJ, Perel JM et al:Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099, 1990
  pubmed

• 45) Kupfer DJ, Frank E, Perel JM et al:Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773, 1992
  pubmed

• 46) Rouillon F, Berdeaux G, Bisserbe JC et al:Prevention of recurrent depressive episodes with milnacipran:consequences on quality of life. J Affect Disord 58:171-180, 2000
  pubmed

• 47) Frank E, Kupfer DJ, Perel JM et al:Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 27:139-145, 1993
  pubmed

• 48) Lin EH, Katon WJ, VonKorff M et al:Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 7:443-449, 1998
  pubmed

• 49) 山本由起子, 五十川浩一, 穐吉條太郎ほか:大うつ病性障害寛解後1年経過と再燃・再発の予測因子. 精神医学 41:861-865, 1999

• 50) Van Londen L, Molenaar RP, Goekoop JG et al:Three-to 5-year prospective follow-up of outcome in major depression. Psychol Med 28:731-735, 1998
  pubmed

• 51) Rao U, Hammen C, Daley SE:Continuity of depression during the transition to adulthood:a 5-year longitudinal study of young women. J Am Acad Child Adolesc Psychiatry 38:908-915, 1999
  pubmed

• 52) Lavori PW, Keller MB, Sceftner W et al:Recurrence after recovery in unipolar MDD:An observational follow up study of clinical predictors and somatic treatment as a mediating factor. Int J Methods Psychiatr Res 4:211-229, 1994

• 53) Boland RJ, Keller MB:Outcome studies of depression in adulthood. In:Shulman KI, Tohen M, Kutcher SP, ed. Mood Disorders Across the Life Span. Wiley & Sons, New York, 1996, pp217-250

• 54) Paykel ES:Relapse, recurrence and chronicity in depression. In:Langer SZ, Brunello N, Racagni G et al, ed. Critical Issues in the Treatment of Affective Disorders. Karger, Basel, vol. 4, 1994, pp9-20

• 55) 神庭重信, 中村 中, 木下徳久:うつ病の長期薬物療法-再発への対応. 精神経誌 96:396-404, 1994

• 56) Harkness KL, Monroe SM, Simons AD et al:The generation of life events in recurrent and non-recurrent depression. Psychol Med 29:135-144, 1999
  pubmed

P.132 掲載の参考文献

• 1) Charney DS, Heninger GR, Breier A:Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751-763, 1984
  pubmed

• 2) Charney DS, Heninger GR:Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 43:1042-1054, 1986
  pubmed

• 3) Mongeau R, Weiss M, de Montigny C et al:Effect of acute, short-and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 37:905-918, 1998

• 4) 鉾之原忠実, 川崎 幸, 望月大介:新規抗うつ薬ミルナシプランの反復投与による5- HT1A受容体機能への影響. (1) 前シナプス神経 (背側縫線核) での検討. 旭化成社内資料.

• 5) Moret C, Briley M:Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 18:1063-1072, 1994
  pubmed

• 6) 貝谷久宣:パニック障害の精神薬理学. 最新 脳と神経科学シリーズ4, 最新の伝達物質-受容体の分子機構と関連神経疾患. (高橋徹, 設楽信行, 清水輝夫編) メジカルビュー, 東京, 1996, pp192-203

• 7) Moret C, Briley M:Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 69:815-822, 1997
  pubmed

• 8) Assie MB, Charveron M, Palmier C et al:Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 31:149-155, 1992
  pubmed

• 9) Bel N, Artigas F:Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology 21:745-754, 1999
  pubmed

• 10) Klein DF, Fink M:Psychiatric reaction patterns to imipramine. Am J Psychiatry 119:432-438, 1962
  pubmed

• 11) Klein DF:Delineation of two drugs-responsive anxiety syndromes. Psychopharmacologia 5:397-408, 1964
  pubmed

• 12) Sheehan DV, Ballenger J, Jacobsen G:Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37:51-59, 1980
  pubmed

• 13) Kalus O, Asnis GM, Rubinson E et al:Desipramine treatment in panic disorder. J Affect Disord 21:239-244, 1991
  pubmed

• 14) Lydiard RB, Morton WA, Emmanuel NP et al:Preliminary report:placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29:183-188, 1993
  pubmed

• 15) Sasson Y, Iancu I, Fux M et al:A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 9:191-196, 1999
  pubmed

• 16) Versiani MV, Montgomery SA, Stahl SM et al:Effect of the novel selective norepinephrine reuptake inhibitor reboxetine on anxiety. American Psychiatric Association, 2001 Annual Meeting, New Orleans, LA May 9, 2001

• 17) Den Boer JA, Westenberg HG:Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder;a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59-74, 1988
  pubmed

• 18) Nyback HV, Walters JR, Aghajanian GK et al:Tricyclic antidepressants:effects on the firing rate of brain noradrenergic neurons. Eur J Pharmacol 32:302-312, 1975
  pubmed

• 19) Charney DS, Heninger GR:Noradrenergic function and the mechanism of action of antianxiety treatment. II:The effect of long-term imipramine treatment. Arch Gen Psychiatry 42:473-481, 1985
  pubmed

• 20) Albus M, Zahn TP, Breier A:Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Eur Arch Psychiatry Clin Neurosci 241:345-351, 1992
  pubmed

• 21) Lecrubier Y, Bakker A, Dunbar G et al:A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:145-152, 1997

• 22) Modigh K, Westberg P, Eriksson E:Superiority of clomipramine over imipramine in the treatment of panic disorder:a placebo-controlled trial. J Clin Psychopharmacol 12:251-261, 1992

• 23) Ballenger JC:Selective serotonin reuptake inhibitors (SSRI) in panic disorder, 笠茂公弘訳, 第11章, パニック障害におけるSSRI, 編訳:久保木富房, 井上雄一, パニック障害病態から治療まで, 日本評論社, 東京, 2001 pp203-229

• 24) Gorman JM:The use of newer antidepressants for panic disorder. J Clin Psychiatry 58 (Suppl 14):54-58, 1997

• 25) Ninan PT:Use of venlafaxine in other psychiatric disorders. Depress Anxiety 12 (Suppl 1):90-94, 2000

• 26) Geracioti TD Jr:Venlafaxine treatment of panic disorder:a case series. J Clin Psychiatry 56:408-410, 1995

• 27) Papp LA, Sinha SS, Martinez JM et al:Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34:207-209, 1998
  pubmed

• 28) Pollack MH, Worthington JJ 3rd, Otto MW et al:Venlafaxine for panic disorder:results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667-670, 1996
  pubmed

• 29) Ansseau M, von Frenckell R, Serre C:Pilot study of milnacipran in panic disorder. Eur Psychiatry 6:103-105, 1991

• 30) Hascoet M, Bourin M, Colombel MC et al:Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65:339-344, 2000

• 31) Hashimoto S, Inoue T, Koyama T:Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berl) 123:182-186, 1996
  pubmed

• 32) 貝谷久宣, 上松正幸:パニック・ディスオーダーの精神薬理学をめぐって. 精神医学レビューNo. 3 パニック・ディスオーダー 編集 高橋 徹, ライフ・サイエンス, 東京, 1992 pp.22-32

• 33) Carr DB, Sheehan DV, Surman OS et al:Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143:483-494, 1986
  pubmed

• 34) 貝谷久宣, 宮前義和:パニック障害における抑うつ状態, パニック障害研究最前線;貝谷久宣/不安・抑うつ臨床研究会編, 日本評論社, 東京, 2000, pp55-78

• 35) 貝谷久宣, 宮前義和:パニック障害における抑うつ状態-パニック性不安うつ病 (2) 臨床的特徴, パニック障害症例集;貝谷久宣/不安・抑うつ臨床研究会編, 日本評論社, 東京, 2001, pp149-168

• 36) Liebowitz MR, Quitkin FM, Stewart JW et al:Phenelzine v imipramine in atypical depression. A preliminary report. Arch Gen Psychiatry 41:669-677, 1984
  pubmed

P.143 掲載の参考文献

• 1) 日本心身医学会教育研修委員会 (編):心身医学の新しい治療指針. 心身医学 31:540-542, 1991

• 2) 久保千春:心身医学. 新臨床内科学第7版. 高久史麿, 尾形悦郎 (編集) 医学書院 24-27, 1997

• 3) 十川 博, 久保千春:気管支喘息と抗不安薬の使い方. 臨床と研究 73:27-30, 1997

• 4) 久保千春:心身医学の診療と展望. 心身医学 37:202, 1997
  Medical*Online

• 5) 中野弘一, 緒方芳久, 花輪治子ほか:心身症・神経症. 薬局52:112-120, 2001

P.150 掲載の参考文献

• 1) Kaplan HI, Sadock BJ, Grebb JA:Kaplan and Sadock's Synopsis of Psychiatry:Behavioral Sciences, Clinical Psychiatry. seventh edition. (井上令一, 四宮滋子 訳:カプラン臨床精神医学テキストDSM-IV診断基準の臨床への展開. 371-375, 医学書院MYW, 9, 東京, 1996)

• 2) Generalized anxiety disorder. In:Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC:American Psychiatric Association Press;1994, 432-436 (高橋三郎, 大野 裕, 染谷俊幸 訳:「DSM-IV精神疾患の分類と診断の手引き」医学書院, 東京, 1995)

• 3) Shader RI, Greenblatt DJ:The pharmacotherapy of acute anxiety:a mini update. In:Bloom FE, Kupfer DJ eds. Psychopharmacology:The Fourth Generation of Progress. New York, NY:Raven Press Ltd;1996, 1341-1348

• 4) Uhlenhuth EH, Balter MB, Mellinger GD et al:Symptom checklist syndromes in the general population. Correlations with psychotherapeutic drug use. Arch Gen Psychiatry 40:1167-1173, 1983
  pubmed

• 5) Blazer DG, Hughes D, George LK et al:Generalized anxiety disorder. In:Robins LN, Reiger DA, eds. Psychiatric Disorders in America:The Epidemiologic Catchment Area Study. New York, NY:Raven Press Ltd;1991, 180-203

• 6) Kessler RC, McGonagle KA, Zhao S et al:Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19, 1994
  pubmed

• 7) Wittchen HU, Zhao S, Kessler RC et al:DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355-364, 1994
  pubmed

• 8) Craig KJ, Brown KJ, Baum A:Environmental factors in the etiology of anxiety. In:Bloom FE, Kupfer DJ, eds. Psychopharmacology:the Forth Generation of Progress. New York, NY:Raven Press Ltd;1995, 1325-1339

• 9) Torgersen S:Genetic factors in anxiety disorders. Arch Gen Psychiatry 40:1085-1089, 1983
  pubmed

• 10) Andrews G, Stewart G, Allen R et al:The genetics of six neurotic disorders:a twin study. J Affect Disord 19:23-29, 1990

• 11) Kendler KS, Neale MC, Kessler RC et al:Generalized anxiety disorder in women. A population-based twin study. Arch Gen Psychiatry 49:267-272, 1992
  pubmed

• 12) Brawman-Mintzer O, Lydiard RB:Biological basis of generalized anxiety disorder. J Clin. Psychiatry 58 (Suppl 3):16-25, 1997

• 13) Dubovsky SL Thomas M:Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 56 (Suppl 2) 38-48, 1995

• 14) Katz RJ, Landau PS, Lott M et al:Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry 34:41-44, 1993
  pubmed

• 15) Graeff FG:Neurotransmitters in the dorsal periaqueductal grey and animal modele of panic disorder. In:Briley M, File S, eds. New Concepts in Anxiety. London, England:MacMillen Press;1991

• 16) Eison MS:Serotonin:a common nuerobiologic substrate in anxiety and depression. J Clin Psychopharmacol 10 (Suppl 3):S26-S30, 1990

• 17) VanderMaelen CP, Matheson GK, Wilderman RC et al:Inhibition of serotonergic dorsal raphe neurons by systemic and iontopheric administration of buspirone, a nonbenzodiazepine anxiolytic drug. Eur J Pharmacol 129:123-130, 1986
  pubmed

• 18) Blier P, de Montigny C:Modification of 5- HT neuron properties by sustained administration of the 5-HT1A agonist gepirone:electrophysiological studies in rat brain. Synapse 1:470-480, 1987
  pubmed

• 19) Schweizer E, Rickels K, Uhlenhuth EH:Issues in the long term treatment of anxiety disorders. In:Bloom FE, Kupfer DJ, eds. Psychopharmacology:The Forth Generation of Progress. New York, NY:Raven Press Ltd;1349-1359, 1995

• 20) Woodman CL, Noyes R Jr, Black DW et al:A 5-year follow-up study of generalized anxiety disorder and panic disorder. J Nerv Ment Dis 187:3-9, 1999
  pubmed

• 21) Rickels K, Case WG, Downing RW et al:One-year follow-up of anxious patients treated with diazepam. J Clin pharmacol 6:32-36, 1986

• 22) Roy-Byrn PP:Generalized anxiety and mixed anxiety-depression:association with disability sand health care utilization. J Clin Psychiatry 57 (Suppl 7):86-91, 1996

• 23) Lin EH, Katon W, VonKorff M et al:Frustrating patients:physician and patient perspectives among distressed high users of medical services. J Gen Interm Med 6:241-246, 1991

• 24) Massion AO, Warshaw MG, Keller MB:Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 150:600-607, 1993
  pubmed

• 25) Simon G, Ormel J, VonKorff M et al:Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 152:352-357, 1995
  pubmed

• 26) Roy-Byrn PP, Katon W:Generalized anxiety disorder in primary care:the precursor/modifier pathway to increased health care utilization. J Clin Psychiatry 56 (Suppl 3):34-38, 1997

• 27) Altshuler LL, Cohen L, Szuba MP et al:Pharmacologic management of psychiatric illness during pregnancy:dilemmas and guidelines. Am J Psychiatry 153:592-606, 1996
  pubmed

• 28) Elia J, Katz IR, Simpson GM:Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 23:531-586, 1987
  pubmed

• 29) Goa KL, Ward A:Buspirone:A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32:114-129, 1986
  pubmed

• 30) Nulman I, Rovet J, Stewart DE et al:Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-262, 1997
  pubmed

• 31) Liebowitz MR, Fyer AJ, Gorman JM et al:Tricyclic therapy of the DSM-III anxiety disorders:a review with implications for further research. J Psychiatr Res 22 (Suppl 1):7-31, 1988

• 32) Kahn RJ, McNair DM, Lipman RS et al:Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 43:79-85, 1986
  pubmed

• 33) Hoehn-Saric R, Mcleod DR, Zimmerli WD:Differential effects of alprazolam and imipramine in generalized anxiety disorder:somatic versus psychic symptoms. J Clin Psychiatry 49:293-301, 1988
  pubmed

• 34) Rickels K, Downing R, Schweizer E et al:Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 50:884-895, 1993
  pubmed

• 35) Rocca P, Fonzo V, Scotta M et al:Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444-450, 1997
  pubmed

• 36) Hedges DW, Reimherr FW, Strong RE et al:An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 32:671-676, 1996
  pubmed

• 37) Lecrubier Y, Bourin M, Moon CA et al:Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95:485-493, 1997
  pubmed

• 38) Rudolph RL, Entsuah R, Chitra R:A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 18:136-144, 1998
  pubmed

• 39) Feighner JP, Entsuah AR, McPherson MK:Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 47:55-62, 1998
  pubmed

• 40) Silverstone PH, Ravindran A:Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxone XR 360 Study Group. J Clin Psychiatry 60:22-28, 1999

• 41) Haskins JT, Aguiar L, Pailsy A et al;for the Venlafaxine XR 210 Study Group:Double-blind, placebo-controlled study once daily venlafaxine XR in outpatient with generalized anxiety disorder [abstract]. Presented at:11th Congress of the European College of Neuropsychopharmacology, October 31-November 4, 1998;Paris, France

• 42) Haskins JT, Rudolph R, Aguiar L et al;for the Venlafaxine XR 214 Study Group:Double blind, placebo-/comparator-controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder [abstract]. Presented at:11th Congress of Neuropsychopharmacology, October 31-November 4, 1998;Paris, France

• 43) Haskins JT, Rudolph R, Aguiar L et al;for the Venlafaxine XR 218 Study Group:Venlafaxine XR is an efficacious short and long term treatment for generalized anxiety disorder [abstract]. Presented at 11th Congress of Neuropsychopharmacology, October 31-November 4, 1998;Paris, France

• 44) Rickels K, Schweizer E:The clinical presentation of generalized anxiety in primary-care settings:practical concepts of classification and management. J Clin Psychiatry 58 (Suppl 11):4-10, 1997

• 45) Ferreri M, Hantouche EG:Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scan 393 (Suppl):102-108, 1998

• 46) Freeman AM 3rd, Westphal JR, Norris GT et al:Efficacy of ondansetron in the treatment of generalized anxiety disorder.Depres Anxiety 5:140-141, 1997

• 47) Smith WT, Londborg PD, Blomgren SL et al:Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine- 3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol 19:125-131, 1999

• 48) Lydiard RB, Ballenger JC, Rickels K:A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. J Clin Psychiatry 58 (Suppl 11):11-18, 1997

• 49) Swartz CM:Betaxolol in anxiety disorders. Ann Clin Psychiatry 10:9-14, 1998
  pubmed

• 50) Rickels K, Schweizer E, Csanalosi I et al:Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45:444-450, 1988
  pubmed

• 51) Scheibe G:Four year follow-up in 40 outpatients with anxiety disorders:buspirone versus lorazepam. Eur J Psychiatry 10:25-34, 1996

• 52) Roerig JL:Diagnosis and management of generalized anxiety disorder. J Am Pharm Assoc 39:811-821, 1999

• 53) Sheehan DV:Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 60 (Suppl 22):23-28, 1999

• 54) Hackett D:Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand 406 (Suppl):30-35, 2000
  pubmed

• 55) Rickels K, Pollack MH, Sheehan DV et al:Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974, 2000
  pubmed

• 56) Davidson JR, DuPont RL, Hedges D et al:Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535, 1999
  pubmed

• 57) Gelenberg AJ, Lydiard RB, Rudolph RL et al:Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. A 6-month randomized controlled study. JAMA 283:3082-3088, 2000
  pubmed

P.165 掲載の参考文献

• 1) Krishnan KR, Goli V, Ellinwood EH et al:Leukoencephalopathy in patients diagnosed as major depressive. Biol Psychiatry 23:519-522, 1988
  pubmed

• 2) Coffey CE, Figiel GS, Djang WT:Leukoencephalopathy in elderly depressed patients refered for ECT. Biol Psychiatry 24:143-161, 1988
  pubmed

• 3) Dupont RM, Jernigan TL, Butters N et al:Subcortical abnormalities detected in bipolar affective disorder using magnetic resonance imaging. Clinical and neuropsychological significance. Arch Gen Psychiatry 47:55-59, 1990
  pubmed

• 4) Fujikawa T, Yamawaki S, Touhouda Y:Incidence of silent cerebral infarction in patients with major depression. Stroke 24:1631-1634, 1993
  pubmed

• 5) Krishnan KR, McDonald WM:Arteriosclerotic depression. Med Hypotheses 44:111-115, 1995
  pubmed

• 6) Krishnan KR, Hays JC, Blazer DG:MRI-defined vascular depression. Am J Psychiatry 154:497-501, 1997
  pubmed

• 7) Alexopoulos GS, Meyers BS, Young RC et al:Clinically defined vascular depression. Am J Psychiatry 154:562-565, 1997
  pubmed

• 8) Miller MD, Paradis CF, Houck PR et al:Rating chronic medical illness burden in geropsychiatric practice and research:application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237-248, 1992
  pubmed

• 9) Alexopoulos GS, Meyers BS, Young RC et al:'Vascular depression' hypothesis. Arch Gen Psychiatry 54:915-922, 1997
  pubmed

• 10) 藤川徳美, 柳井一郎, 堀口 淳ほか:Vascular depressionの診断に関する諸問題. 臨床精神医学 28:1067-1072, 1997

• 11) Chemerinski E, Robinson RG:The neuropsychiatry of stroke. Psychosomatics 41:5-14, 2000
  pubmed

• 12) Robinson RG, Szetela B:Mood change following left hemispheric brain injury. Ann Neurol 9:447-453, 1981
  pubmed

• 13) Morris PL, Robinson RG, Raphael B et al:Lesion location and poststroke depression. J Neuropsychiatry Clin Neurosci 8:399-403, 1996
  pubmed

• 14) Herrmann M, Bartels C, Wallesch CW:Depression in acute and chronic aphasia:symptoms, pathoanatomical-clinical correlations and functional implications. J Neurol Neurosurg Psychiatry 56:672-678, 1993
  pubmed

• 15) Dam H, Pedersen HE, Ahlgren P:Depression among patients with stroke. Acta Psychiatr Scand 80:118-124, 1989
  pubmed

• 16) House A, Dennis M, Warlow C et al:Mood disorders after stroke and their relation to lesion location. A CT scan study. Brain 113:1113-1129, 1990

• 17) Shimoda K, Robinson RG:The relationship between poststroke depression and lesion location in long-term follow-up. Biol Psychiatry 45:187-192, 1999
  pubmed

• 18) Carson AJ, MacHale S, Allen K et al:Depression after stroke and lesion location:a systematic review. Lancet 356:122-126, 2000
  pubmed

• 19) Pearlson GD, Kubos KL, Robinson RG:Effect of anterior-posterior lesion location on the asymmetrical behavioral and biochemical response to cortical suction ablations in the rat. Brain Res 293:241-250, 1984
  pubmed

• 20) Kinsbourne M, Bemporad B:Lateralization of emotion:a model and the evidence. In:Fox NA, Davidson RJ (eds.) The Psychobiology of Affective Development. Hinsdale, NJ:Lawrence Erlbaum Associates, 1984

• 21) Krishnan KR:Neuroanatomic substrates of depression in the elderly. J Geriatr Psychiatry Neurol 6:39-58, 1993
  pubmed

• 22) George MS, Ketter TA, Post RM:Prefrontal cortex dysfunction in clinical depression. Depression 2:59-72, 1994

• 23) Robinson RG, Kubos KL, Starr LB et al:Mood disorders in stroke patients. Importance of location of lesion. Brain 107:81-93, 1984
  pubmed

• 24) Mayberg HS, Solomon DH:Depression in Parkinson's disease:a biochemical and organic viewpoint, in Behavioral Neurology of Movement Disorders:Advances in Neurology, vol 65. Edited by Weiner WJ, Lang AE. New York, Raven Press, pp49-60, 1995

• 25) Schwartz JA, Speed NM, Mountz JM et al:99mTc-hexamethylpropyleneamine oxime single photon emission CT in poststroke depression. Am J Psychiatry 147:242-244, 1990
  pubmed

• 26) Yamaguchi S, Kobayashi S, Koide H et al:Longitudinal study of regional cerebral blood flow changes in depression after stroke. Stroke 23:1716-1722, 1992
  pubmed

• 27) Fazekas F, Chawluk JB, Alavi A et al:MR signal abnormalities at 1.5T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149:351-356, 1987
  pubmed

• 28) Goodwin GM, Austin MP, Dougall N et al:State changes in brain activity shown by the uptake of 99mTc-exametazime with single photon emission tomography in major depression before and after treatment. J Affect Disord 29:243-253, 1993
  pubmed

• 29) Bench CJ, Frackowiak RS, Dolan RJ:Changes in regional cerebral blood flow on recovery from depression. Psychol Med 25:247-261, 1995
  pubmed

• 30) Drevets WC, Videen TO, Price JL et al:A functional anatomical study of unipolar depression. J Nuerosci 12:3628-3641, 1992
  pubmed

• 31) Awata S, Ito H, Konno M et al:Regional cerebral blood flow abnormalities in late-life depression:relation to refractoriness and chronification. Psychiatry Clin Nuerosci 52:97-105, 1998
  pubmed

• 32) Zheng XM:Regional cerebral blood flow changes in drug-resistant depressed patients following treatment with transcranial magnetic stimulation:a statistical parametric mapping analysis. Psychiatry Res 100:75-80, 2000
  pubmed

• 33) Kimura M, Robinson RG, Kosier JT:Treatment of cognitive impairment after poststroke depression:a double-blind treatment trial. Stroke 31:1482-1486, 2000
  pubmed

• 34) Chemerinski E, Robinson RG, Arndt S et al:The effect of remission of poststroke depression on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 189:421-425, 2001

• 35) Taragano FE, Allegri R, Vicario A et al:A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. Int J Geriatr Psychiatry 16:254-260, 2001
  pubmed

• 36) Lenzi GL Grigoletto F, Gent M et al:Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial. Stroke 25:1552-1558, 1994
  pubmed

• 37) Goldstein LB:Pharmacologic modulation of recovery after stroke:clinical data. J Neurol Rehab 5:129-140, 1991

• 38) Lipsey JR, Robinson RG, Pearlson GD et al:Nortriptyline treatment of post-stroke depression:a double-blind study. Lancet 1:297-300, 1984
  pubmed

• 39) Reding MJ, Orto LA, Winter SW et al:Antidepressant therapy after stroke. A double-blind trial. Arch Neurol 43:763-765, 1986
  pubmed

• 40) Lauritzen L, Bendsen BB, Vilmar T et al:Post-stroke depression:combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacology (Berl) 114:119-122, 1994
  pubmed

• 41) Andersen G, Vestergaard K, Lauritzen L:Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25:1099-1104, 1994
  pubmed

• 42) Wiart L, Petit H, Joseph PA et al:Fluoxetine in early poststroke depression:a double-blind placebo-controlled study. Stroke 31:1829-1832, 2000
  pubmed

• 43) Robinson RG, Shultz SK, Castillo C et al:Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke:a placebo-controlled, double-blind study. Am J Psychiatry 157:351-359, 2000

• 44) Grade C, Redford B, Chrostowski J et al:Methylphenidate in early poststroke recovery:a double-blind, placebo-controlled study. Arch Phys Med Rehabil 79:1047-1050, 1998
  pubmed

• 45) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997
  pubmed

• 46) Sheehan DV, Lecrubier Y, Sheehan KH et al:The Mini-International Neuropsychiatric Interview (M.I.N.I.):the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33, 1998

• 47) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価-塩酸イミプラミンを対照薬とした第III相臨床試験-. 臨床医薬 11:819-842, 1995
  Medical*Online

• 48) 遠藤俊吉, 三浦貞則, 村崎光邦ほか:うつ病・うつ状態に対する新しい抗うつ薬塩酸ミルナシプランの臨床評価. -塩酸ミァンセリンを対照薬とした第III相臨床試験-臨床評価 23:39-46, 1995

• 49) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4):41-46, 1996

• 50) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 51) Moller HJ:Are all antidepressants the same? J Clin Psychiatry 61 (Suppl 6):24-28, 2000

P.177 掲載の参考文献

• 1) 高橋三郎, 大野 裕, 染矢俊幸訳:DSM-IV 精神疾患の分類と診断の手引, 医学書院, 東京, 1995

• 2) 北見公一, 奥瀬 哲:脳神経外科領域における筋収縮性頭痛患者の心理背景. 心身医療 3:400-405, 1991

• 3) 北見公一:各科の診断基準Psychosomatic Symposium on Headache 2000 Proceedingsファルマシア. 東京, 2001, pp16-19

• 4) 北見公一, 奥瀬 哲ほか:慢性疼痛患者の脳神経外科学的ならびに臨床心理学的検討. 心身医学 35:569-575, 1995

• 5) 北見公一:難治性疼痛の種類と治療の概観 (機能的脳神経外科-最近の進歩). 医学のあゆみ 189:744-750, 1999

• 6) 北見公一:筋筋膜性疼痛症候群の病態の臨床研究. Pain research 14:153, 1999

• 7) 北見公一:脳の痛み. 心の痛み-慢性痛からの解放をめざして-. 三輪書店, 東京, 1998

• 8) Schoenen J, Sandor PS:Headache. In Textbook of Pain 4th ed. By Wall PD and Melzack R. Churchill Livingstone, 1999, pp761-798

• 9) Jorge RE, Leston JE, Arndt S et al:Cluster headaches:association with anxiety disorders and memory deficits. Neurology 11;53:543-547, 1999

• 10) McCain GA:Fibromyalgia and myofascial pain syndromes. Textbook of Pain. III rd.ed (ed.by Wall PD and Melzack R) Churchill Livingstone, pp475-493, 1994

• 11) Hong CZ, Simons DG:Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 79:863-872, 1998
  pubmed

• 12) Roth RS, Horowitz K, Bachman JE:Chronic myofascial pain:knowledge of diagnosis and satisfaction with treatment. Arch Phys Med Rehabil 79:966-970, 1998
  pubmed

• 13) Kellgren JH:A preliminary account of referred pain arising from muscle. Br Med J 1:325-327, 1938

• 14) Travell G, Simons DG:Myofascial Pain and Dysfunction:The Trigger Point Mannual. Williams & Wilkins, Baltimore, 1983

P.187 掲載の参考文献

• 1) Allsopp LF, Cooper GL, Poole PH:Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 9:64-70, 1984
  pubmed

• 2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorder Fourth Edition (DSM-IV) APA Wachington DC, 1994

• 3) 朝倉聡, 傳田健三, 小山 司:対人恐怖/社会恐怖の薬物療法. 臨床精神医学 29:1121-1128, 2000
  Medical*Online

• 4) Barr LC, Goodman WK, Anand A et al:Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295, 1997
  pubmed

• 5) Beaumont G:A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res 5 (Suppl 5):116-123, 1977

• 6) Bisserbe JC, Lane RM, Flament MF et al:A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 12:82-93, 1997

• 7) Chen CJ:The obsessive quality and clomipramine treatment in PTSD. Am J Psychiatry 148:1087-1088, 1991
  pubmed

• 8) Christenson GA, Mackenzie TB, Mitchell JE et al:A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 148:1566-1571, 1991
  pubmed

• 9) Christenson GA, Crow SJ:The characterization and treatment of trichotillomania. J Clin Psychiatry 57 (Suppl 8):42-47, 1996

• 10) Connor KM, Sutherland SM, Tupler LA et al:Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry 175:17-22, 1999
  pubmed

• 11) Davidson J, Kudler H, Smith R et al:Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 47:259-266, 1990
  pubmed

• 12) Foa BE, Davidson RT, Frances A:Selecting the initial mesication. The expert consensus guideline series:treatment of posttraumatic stress disorder. J Clin Psychiatry 60 (Suppl 16):18-23, 1999

• 13) Frank JB, Kosten TR, Giller EL Jr et al:A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorde Am J Psychiatry 145:1289-1291, 1988

• 14) Freeman CP, Trimble MR, Deakin JF et al:Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder:a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55:301-305, 1994
  pubmed

• 15) Goodman WK, Price LH, Delgado PL et al:Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47:577-585, 1990
  pubmed

• 16) Greist JH, Jefferson JW, Kobak KA et al:Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 52:53-60, 1995
  pubmed

• 17) Hamner MB, Frueh BC:Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. Int Clin Psychopharmacol 13:233-234, 1998

• 18) Hertzberg MA, Feldman ME, Beckham JC et al:Lack of efficacy for fluoxetine in PTSD:a placebo controlled trial in combat veterans. Ann Clin Psychiatry 12:101-105, 2000
  pubmed

• 19) Hoehn-Saric R, Ninan P, Blank DW et al:Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 57:76-82, 2000

• 20) Hollander E:Treatment of obsessive-compulsive spectrum disorder with SSRIs. Br J Psychiatry 173 (Suppl 35):7-12, 1998

• 21) Hollander E, Allen A, Kwon J et al:Clomipramine vs desipramine crossover trial in body dysmorphic disorder:selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56:1033-1039, 1999
  pubmed

• 22) Kelsey JE:Venlafaxine in social phobia. Psychopharmacol Bull 31:767-771, 1995
  pubmed

• 23) Koran LM, McElroy SL, Davidson JR et al:Fluvoxamine versus clomipramine for obsessive-compulsive disorder:a double-blind comparison. J Clin Psychopharmacol 16:121-129, 1996
  pubmed

• 24) Kosten TR, Frank JB, Dan E et al:Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179:336-370, 1991

• 25) Liebowitz MR, Schneier F, Campeas R et al:Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49:290-300, 1992
  pubmed

• 26) Marshall WK:Clinical experience in the treatment of phobic disorders. J Int Med Res 5 (Suppl 5):65-70, 1977

• 27) Ninan PT, Knight B, Kirk L et al:A controlled trial of venlafaxine in trichotillomania:interim phase I results. Psychopharmacol Bull 34:221-224, 1998

• 28) Ninan PT, Rothbaum BO, Marsteller FA et al:A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry 61:47-50, 2000
  pubmed

• 29) Noorbala AA, Hosseini SH, Mohammadi MR et al:Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder:a double- blind, placebo-controlled trial. J Clin Pharm Ther 23:155-159, 1998

• 30) Papart P, Ansseau M:Milnacipran et trouble obsessionnel-compulsif:etude d'un cas. Psychiatry & Psychobiol 5:325-327, 1990

• 31) Piccinelli M, Pini S, Bellantuono C et al:Efficacy of drug treatment in obsessive-compulsive disorder:A meta-analytic review. Br J Psychiatry 166:424-443, 1995
  pubmed

• 32) Pigott TA, Seay SM:A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106, 1999
  pubmed

• 33) Rauch SL, O'Sullivan RL, Jenike MA:Open treatment of obsessive-compulsive disorder with venlafaxine:a series of ten cases. J Clin Psychopharmacol 16:81-84, 1996

• 34) Reist C, Kauffmann CD, Haier RJ:A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 146:513-516, 1989
  pubmed

• 35) Schneier FR:Treatment of social phobia with antidepressants. J Clin Psychiatry 62 (Suppl 1):43-48, 2001

• 36) Simpson HB, Schneier FR, Campeas RB et al:Imipramine in the treatment of social phobia. J Clin Psychopharmacol 18:132-135, 1998
  pubmed

• 37) Streichenwein SM, Thornby JI:A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 152:1192-1196, 1995
  pubmed

• 38) Swedo SE, Leonard HL, Rapoport JL et al:A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 321:497-501, 1989
  pubmed

• 39) Thoren P, Asberg M, Cronholm B et al:Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 37:1281-1285, 1980

• 40) van der Kolk BA, Dreyfuss D, Michaels M et al:Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 55:517-522, 1994
  pubmed

• 41) van der Linden, Stein DJ, Balkom AJ:The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia):a meta-analysis of randomised controlled trials. Int Clin Psychopharacol 15 (Suppl 2):S15-23, 2000

• 42) Waxman D:A clinical trial of clomipramine and diazepam in the treatment of phobic and obsessional illness. J Int Med Res (Suppl 5):99-110, 1977

• 43) Yaryura-Tobias JA, Neziroglu FA:Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 53:653-654, 1996
  pubmed

• 44) Zohar J, Judge R:Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 169:468-474, 1996

第4章 治療上の注意点

P.202 掲載の参考文献

• 1) Macher JP, Sichel JP, Serre C et al:Double- blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82, 1989
  pubmed

• 2) Ansseau M, von Frenckell, Mertens C et al:Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 98:163-168, 1989
  pubmed

• 3) Ansseau M, von Frenckel R, Papart P et al:Controlled comparison of milnacipran (F2207) 200mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 4:221-227, 1989

• 4) Ansseau M, Papart P, Troisfontaines B et al:Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 114:131-137, 1994
  pubmed

• 5) 小野寺勇夫, 伊藤公一, 岡田文彦ほか:第4世代の抗うつ薬TN-912 (塩酸ミルナシプラン) の後期第II相臨床試験 (用量設定試験) について. 臨床医薬10巻:2445-2471, 1994

• 6) 村崎光邦, 三浦貞則, 上島国利ほか:新抗うつ薬塩酸ミルナシプラン (TN-912) のうつ病. うつ状態に対する臨床効果-用量設定試験 (オープン試験) -. 臨床医薬11巻 (Suppl 3):85-101, 1995

• 7) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997
  pubmed

• 8) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4) 35-39, 1996

• 9) Lopez-Ibor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4) 41-46, 1996

• 10) Clerc G:Antidepressant efficacy and tolerability of milnacipran, a dual serotoinn and noradrenaline reuptake inhibitor:a comparison with fluvoxamine. Int Clin Psycho Pharmacol 16:145-151, 2001

• 11) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 12) von Frenckell R, Ansseau M, Serre C et al:Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 5:49-56, 1990
  pubmed

• 13) Guelfi JD, Ansseau M, Corruble E et al:A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 13:121-128, 1998
  pubmed

• 14) 高橋義人, 小山 司:ラット前頭前野内側部細胞外モノアミン動態に及ぼすmilnacipran (TN-912) 急性投与の影響. 基礎と臨床 29:27-32, 1995
  Medical*Online

• 15) Arana GW, Rosenbaum JF:Antidepressant drugs. Handbook of Psychiatric Drug Therapy (Fourth Edition), Lippincott Williams & Wilkins, Philadelphia, 2000, pp76-85, pp90-100

• 16) Tignol J, Pujol DJ, Chartres JP et al:Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 97:157-165, 1998

• 17) 高橋明比古, 村崎光邦, 稲見充昭ほか:新規抗うつ薬塩酸ミルナシプランの高齢者に対する臨床的有効性の検討. 臨床医薬 11 (Suppl 3):103-118, 1995

• 18) Alexopoulos GS, Salzman C:Treatment of depression with heterocyclic antidepressants, monoamine oxidase inhibitors, and psychomotor stimulants. Clinical Geriatric Psychopharmacology (Third Edition), ed. by Salzman C, Williams & Wilkins, Baltimore, 1998, pp188-208

• 19) Rouet RH, Tisne-Versailles J, Adamantidis MM et al:Comparative in vivo and in vitro study of the cardiac effects of midalcipran and imipramine. Fundam Clin Pharmacol 3:237-244, 1989
  pubmed

• 20) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran:an overview. Inl Clin Psychopharmacol 11 (Suppl 4) 47-51, 1996

• 21) Schweizer E, Weise C, Clary C et al:Placebo-controled trial of venlafaxine fbr the treatment of major depression. J Clin Psychopharmacol 11:233-236, 1991

• 22) Kelsey J:Dose-response relationship with venlafaxine. J Clin Psychopharmacol 16:S21-S26;discussion 26S-28S, 1996

• 23) Mendels J,Johnston R Mattes J et al:Efficacy and safety of b. i. d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169-174, 1993

• 24) Khan A, Upton GV, Rudolph RL et al:The use of venlafaxine in the treatment of major depression and major depression associated with anxiety:a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 18:19-25, 1998

• 25) Rudolph RL Fabre LF, Feighner Jp et al:A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122, 1998
  pubmed

• 26) Guelfi JD, White C, Hackett D et al:Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin psychiatry 56:450-458, 1995
  pubmed

• 27) Thase ME:Effects of venlafaxine on blood pressure:a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508, 1998
  pubmed

• 28) Cunningham LA:Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 9:157-164, 1997

• 29) Wyeth Laboratories Inc.:Package insert of Effexor (venlafaxine hydrochloride) and Effexor XR, 2000

• 30) Entsuah AR, Rudolph RL, Hackett D et al:Efficacy of venlafaxine and placebo during long-term treatment of depression:a pooled analysis of relapse rates. Int Clin Psychopharmacol 11:137-145, 1996
  pubmed

• 31) Troy SM, Schultz RW, Parker VD et al:The effect of renal disease on the disposition of venlafaxineacol Clin Pharmacol Ther 56:14-21, 1994
  pubmed

• 32) Klamerus KJ, Parker VD, Rudolph RL et al:Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Phamacotherapy 16:915-923, 1996

• 33) Khan A, Rudolph R, Baumel B et al:Venlafaxine in depressed geriatric outpatients:an open-label clinical study. Psychopharmacol Bull 31:753-758, 1995
  pubmed

• 34) Dierick M:An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8:169-178, 1996

• 35) Amore M, Ricci M, Zanardi R et al:Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 46:293-296, 1997
  pubmed

• 36) Zimmer B, Kant R, Zeiler D et al:Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Int J Psychiatry Med 27:353-364, 1997

• 37) Parsons AT, Anthony RM, Meeker JE:Two fatal cases of venlafaxine poisoning. J Anal Toxicol 20:266-268, 1996
  pubmed

• 38) Levine B, Jenkins AJ, Queen M et al:Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 20:502-505, 1996

P.214 掲載の参考文献

• 1) Grisso T, Appelbaum PS:Assessing competence to consent to treatment:A guide for physicians and other health professionals. Oxford Univ Press, New York, 1998

• 2) 大坪天平, 上島国利:SNRIはSSRIを凌ぐか, SNRIsの臨床応用. 臨床精神薬理3:345- 351, 2000

• 3) Papp LA, Sinha SS, Martinez JM et al:Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34:207-209, 1998
  pubmed

• 4) Rauch SL, O'Sullivan RL, Jenike MA:Open treatment of obsessive-compulsive disorder with venlafaxine:a series of ten cases.J Clin Psychopharmacol 16:81-84, 1996

• 5) Kelsey JE:Venlafaxine in social phobia. Psychopharmacol Bull 31:767-771, 1995
  pubmed

• 6) Hamner MB, Frueh BC:Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran post-traumatic stress disorder. Int Clin Psychopharmacol 13:233-234, 1998

• 7) Davidson JR, DuPont RL Hedges D et al:Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535, 1999
  pubmed

• 8) 森田行夫:新薬の開発動向. 新規SNRI Milnacipran. 脳の科学 20:447-452, 1998

• 9) Leinonen E, Lepola U, Koponen H et al:Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 96:497-504, 1997
  pubmed

• 10) Dierick M:An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8:169-178, 1996

• 11) Sirey JA, Bruce ML, Alexopoulos GS et al:Perceived stigma as predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 158:479-481, 2001

• 12) Thase ME:Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 60 (Suppl 6):15-19, 1999

• 13) 川勝 忍, 十束支朗, 吉村悦郎ほか:塩酸ミルナシプランの長期投与による有用性の検討. 臨床医薬 10, 2715-2735, 1994
  Medical*Online

• 14) Spencer CM, Wilde MI:Milnacipran. A review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 15) Myers ED, Calvert EJ:The effect of forewarning on the occurrence of side-effects and discontinuance of medication in patients on dothiepin. J Int Med Res 4:237-240, 1976
  pubmed

• 16) 高橋明比古:SNRIはSSRIを凌ぐか. SNRIの国内での臨床成績. 臨床精神薬理 3:337-347, 2000

P.226 掲載の参考文献

• 1) 松原良次, 松原繁廣, 小山 司:SNRIの薬効・薬理. 臨床精神薬理 3:325-330, 2000

• 2) Harvey AT, Rudolph RL, Preskorn SH:Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509, 2000
  pubmed

• 3) Turcotte JE, Debonnel G, de Montigny C et al:Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24:511-521, 2001
  pubmed

• 4) 村崎光邦:Milnacipranの基礎と臨床. 臨床精神薬理 3:363-380, 2000

• 5) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran, an overview. Int Clin Psychopharmacol 11 (Suppl 4):47-51, 1996

• 6) Briley M:Milnacipran, a well-tolerated specific serotonin and noradrenaline reuptake inhibiting antidepressant. CNS Drug Reviews 4:137-148, 1998

• 7) Puech A, Montgomery SA, Prost JF et al:Milnacipran, a new serotonin and noradrenaline reuptake inhibitor:an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108, 1997
  pubmed

• 8) Spencer CM, Wilde MI:Milnacipran. A review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 9) 山下 格, 松原良次, 小野寺勇夫ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価 塩酸イミプラミンを対照薬とした第III相臨床試験. 臨床医薬 11:819-842, 1995
  Medical*Online

• 10) 遠藤俊吉, 三浦貞則, 宮坂松衛ほか:うつ病・うつ状態に対する新しい抗うつ薬塩酸ミルナシプランの臨床評価 塩酸ミァンセリンを対照薬とした第III相臨床試験. 臨床評価 23:39-64, 1995

• 11) Rouillon F, Warner B, Pezous N et al:Milnacipran efficacy in the prevention of recurrent depression:12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol 15:133-140, 2000

• 12) Briley M:Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). a review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol Clin Exp 13:99-111, 1998

• 13) 田島 治:SNRIの相互作用と副作用. 臨床精神薬理 3:353-361, 2000

• 14) Holliday SM, Benfield P:Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294, 1995
  pubmed

• 15) Danjou P, Hackett D:Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 10 (Suppl 2):15-20, 1995

• 16) Morton WA, Sonne S, Verga MA:Venlafaxine:a structurally unique and novel antidepressant. Ann Pharmacother 29:387-395, 1995
  pubmed

• 17) Horst WD, Preskorn SH:Mechanisms of action and clinical characteristics of three atypical antidepressants:venlafaxine, nefazodone, bupropion. J Affect Disord 51:237-254, 1998
  pubmed

• 18) Kirby D, Ames D:Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patient. Int J Geriatr Psychiatry 16:484-493, 2001
  pubmed

• 19) Thor KB, Katofiasc MA:Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274:1014-1024, 1995

• 20) Berk M, du Plessis AD, Birkett M et al:An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Int Clin Pschopharmacol 12:137-140, 1997

• 21) 和田雄治:SNRI系抗うつ薬・尿失禁治療薬塩酸デュロキセチン. 脳の科学 20:921-926, 1998

• 22) Wong DT, Bymaster FP, Mayle DA et al:LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1:23-33, 1993
  pubmed

• 23) Thase ME:Effects of venlafaxine on blood pressure:a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508, 1998
  pubmed

• 24) Caron J, Libersa C, Hazard JR et al:Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 3:493-500, 1993
  pubmed

• 25) Sharma A, Goldberg MJ, Cerimele BJ:Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161-167, 2000
  pubmed

• 26) Leonard B:Antidepressants:the challenge of improved tolerability. Drugs in focus 3:23-31, 2001

• 27) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4) 35-39, 1996

• 28) Sachs GS, Printz DJ, Kahn DA et al:The Expert Consensus Guideline Series:Medication Treatment of Bipolar Disorder 2000.

• 29) Discussion (司会, 村崎光邦):SNRIの意義と位置付け. 4:1216-1219, 2001

• 30) 岡田 俊:Fluvoxamineの消化器系副作用に対するmosapride citrateの有効性. 精神科治療学 16:401-404, 2001

• 31) 上田展久, 吉村玲児, 新開浩二ほか:Fluvoxamineによる嘔気と5-HIAA濃度の関連. 臨床精神薬理 4:1549-1552, 2001

• 32) Sachs GS, Guille C:Weight gain associated with use of psychotropic medications. J Clin Psychiatry 60 (Suppl 21):16-19, 1999

• 33) Fava M:Weight gain and antidepressants. J Clin. Psychiatry 61 (Suppl 11):37-41, 2000

• 34) Ferguson JM:The effects of antidepressants on sexual functioning in depressed patients:a review. J Clin Psychiatry 62 (Suppl 3):22-34, 2001

• 35) Ellison JM:Antidepressant-induced sexual dysfunction:review, classification, and suggestions for treatment. Harv Rev Psychiatry 6:177-189, 1998
  pubmed

• 36) Zajecka J:Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 62 (Suppl 3):35-43, 2001

• 37) Black K, Shea C, Dursun S et al:Selective serotonin reuptake inhibitor discontinuation syndrome:proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261, 2000
  pubmed

• 38) Zajecka J, Tracy KA, Mitchell S:Discontinuation symptoms after treatment with serotonin reuptake inhibitors:a literature review. J Clin Psychiatry 58:291-297, 1997
  pubmed

• 39) Wolfe RM:Antidepressant withdrawal reactions. Am Fam Physician 56:455-462, 1997
  pubmed

• 40) Garner EM, Kelly MW, Thompson DF:Tricyclic antidepressant withdrawal syndrome. Ann Pharmacother 27:1068-1072, 1993
  pubmed

• 41) Edwards JG, Anderson I:Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533, 1999
  pubmed

• 42) Dalden A, Stewart DE:Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can J Psychiatry 46:258-262, 2001
  pubmed

P.238 掲載の参考文献

• 1) 高橋明比古, 川口 毅, 笠原友幸ほか:抗うつ薬塩酸ミルナシプラン (TN-912) の第I相試験. 臨床医薬11 (Suppl 3):3-69, 1995

• 2) 高橋明比古, 川口 毅, 笠原友幸ほか:塩酸ミルナシプラン15mg錠の健常人による吸収排泄試験, -食事の及ぼす影響並びに反復投与による薬物動態の検討-. 臨床医薬11 (Suppl 3):119-132, 1995

• 3) 中道 昇, 関野久之, 乃村昌臣ほか:高齢者における塩酸ミルナシプランの薬物動態の検討. 臨床医薬11 (Suppl 3):133-143, 1995

• 4) Spencer CM, Wilde MI:Milnacipran:A review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 5) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl 4):15-27, 1996

• 6) 鶴田一壽, 鶴井一幸, 岡崎勝也ほか:塩酸ミルナシプランのヒトP450を介する薬物相互作用の検討. 医薬品研究31:659-667, 2000

• 7) Morton WA, Sonne S, Verga MA:Venlafaxine:a structurally unique and novel antidepressant. Ann Pharmacother 29:387-395, 1995
  pubmed

• 8) Fukuda T, Yamamoto I, Nishida Y et al:Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47:450-453, 1999
  pubmed

• 9) Caccia S:Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302, 1998
  pubmed

• 10) Holliday SM, Benfield P:Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294, 1995
  pubmed

• 11) Ball SE, Ahern D, Scatina J et al:Venlafaxine:in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism;comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharamacol 43:619-626, 1997

P.243 掲載の参考文献

• 1) Clerc G, the Milnacipran/Fluvoxamine Study Group:Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor:a comparison with fluvoxamine. Int Clin Psychopharmacol 16:145-151, 2001

• 2) Delini-Stula A:Milnacipran:an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol Clin Exp 15:255-260, 2000

• 3) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39, 1996

• 4) Lopez-lbor J, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl 4):41-46, 1996

• 5) Steen A, Den Boer JA:A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 12:269-281, 1997
  pubmed

• 6) 寺尾 岳:SSRIsとSNRIsの臨床的位置づけ:私の臨床経験から. 臨床精神医学 30:1047-1053, 2001
  Medical*Online

第5章 安全性とQOL

P.254 掲載の参考文献

• 1) Angst J:How recurrent and predictable is depressive illness? In:Long-Term Treatment of Depression ( ed by Montgomery SA, Rouillon F), John Wiley and Son., New York, 1992,pp 1-13

• 2) Damiano AM:The Sickness Impact Profile. In:Quality of life and pharmacoeconomics in clinical trials (ed by Spilker B) Lippincott-Raven Publishers, Philadelphia, 1996,pp347-354

• 3) Dardennes R, Berdeaux G, Lafuma A et al:Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs:a modeling approach. Eur Psychiatry 14:152-162, 1999
  pubmed

• 4) Dunbar GC, Stoker MJ, Hodges TCP et al:The development of SBQOL:a unique scale for measuring quality of life. Br J Health Economics 2:65-74, 1992

• 5) Dupuy HJ:Self-presentations of general psychological well-being of American adults. Presented at the 106th annual meeting of the American Public Health Association;Oct.15-19, 1978, Los Angeles, California

• 6) Einarson TR, Arikian S, Sweeney S et al:A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 17:136-153, 1995

• 7) Elkin I, Parloff MB, Hadley SW et al:NIMH Treatment of Depression Collaborative Research Program. Background and research plan. Arch Gen Psychiatry 42:305-316, 1985
  pubmed

• 8) 福原俊一:いまなぜQOLか-患者立脚型アウトカムとしての位置づけ. 臨床のためのQOL ハンドブック (池上直己, 福原俊一, 下妻晃二郎, 池田俊也編) 医学書院, 東京, 2001, pp2-7

• 9) 福原俊一, 鈴鴨よしみ:健康プロファイル型尺度 (SF-36を中心に). 臨床のためのQOL ハンドブック (池上直己, 福原俊一, 下妻晃二郎, 池田俊也編) 医学書院, 東京, 2001, pp32-42

• 10) Giller E Jr, Bialos D, Riddle MA et al:MAOI treatment response:multiaxial assessment. J Affect Dis 14:171-175, 1988
  pubmed

• 11) Goethe JW, Fischer EH:Functional impairment in depressed inpatients. J Affect Dis 33:23-29, 1995
  pubmed

• 12) Hays RD, Sherbourne CD, Mazel RM:The RAND 36-item Health Survey 1.0. Health Econ 2:217-227, 1993

• 13) Hirschfeld PRMA:Psychosocial predictors of outcome in depression. In:Psychopharmacology:The fourth generation of progress (ed by Bloom FE, Kupfer DJ), Raven Press, Ltd., New York, 1995, 11, 1113-1121

• 14) Keller MB, Lavori PW, Mueller TI et al:Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:769-773, 1992

• 15) Lenderking WR, Tennen H, Nackley JF et al:The effects of venlafaxine on social activity level in depressed outpatients. J Clin Psychiatry 60:157-163, 1999
  pubmed

• 16) Lonnqvist J, Sintonen H, Syvalahti E et al:Antidepressant efficacy and quality of life in depression:a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 89:363-369, 1994
  pubmed

• 17) Lyness JM, Caine ED, Conwell Y et al:Depressive symptoms, medical illness, and functional status in depressed psychiatric inpatients.Am J Psychiatry 150:910-915, 1993
  pubmed

• 18) Markowitz JS, Weissman MM, Ouellette R et al:Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992, 1989
  pubmed

• 19) Mintz J, Mintz LI, Arruda MJ et al:Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49:761-768, 1992
  pubmed

• 20) 宮田量治:薬物療法の実際:新薬とQOLの改善. 精神科治療学 16:1267-1278, 2001

• 21) Priest RG:Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Clin Ther 18:347-358, 1996
  pubmed

• 22) Rouillon F, Berdeaux G, Bisserbe JC et al:Prevention of recurrent depressive episodes with milnacipran:consequences on quality of life. J Affect Dis 58:171-180, 2000
  pubmed

• 23) Rouillon F, Warner B, Pezous N et al:Milnacipran efficacy in the prevention of recurrent depression:a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol 15:133-140, 2000

• 24) Rounsaville BJ, Weissman MM, Prusoff BA et al:Marital disputes and treatment outcome in depressed women. Compr Psychiatry 20:483-490, 1979
  pubmed

• 25) Rudolph R, Derivan AT, Pederson R:Quality of life:Assessment in drug development. APA Annual Meeting, Washington, DC, May, 1992

• 26) Stoker MJ, Dunbar GC, Beaumont G:The Smith Kline Beecham 'quality of life' scale:avalidation and reliability study in patients with affective disorder. Quality of Life Research 1:385-395, 1992

• 27) Surtees PG, Barkley C:Future imperfect:the long-term outcome of depression. Br J Psychiatry 1 64:327-341, 1994

• 28) Turner R:Quality of life:experience with sertraline. Int Clin Psychopharmacol 9 (Suppl 3):27-31, 1994

• 29) Walker V, Streiner DL, Novosel S et al:Health-related quality of life in patients with major depression who are treated with moclobemide. Int Clin Psychopharmacol 15 (Suppl 2):S60-S67, 1995

• 30) Weissman MM:Panic disorder:impact on quality of life. J Clin Psychiatry (Suppl) 52:6-8, 1991

• 31) Weiden PJ, Olfson M:Cost of relapse in schizophrenia. Schizophr Bull 21:419-429, 1995
  pubmed

P.265 掲載の参考文献

• 1) Muller TI, Leon AC, Keller MB et al:Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156:1000-1006, 1999

• 2) 上島国利:抗うつ薬のコンプライアンス. 医学のあゆみ 160:791-794, 1992
  Medical*Online

• 3) Elizabeth HB, Michael VK, Wayne K et al:The role of primary care physician in patient's adherence to antidepressant therapy. Medical Care 33:67-74, 1995

• 4) Dara CB, Bonnie LS:Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. Patient Educ Couns 40:173-185, 2000

• 5) Katon W, Rutter C, Ludman EJ et al:A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 58:241-247, 2001
  pubmed

• 6) 高橋良監訳:うつ病診療の問題点. 医学書院, 東京, 1987

• 7) Eisen SA, Miller DK, Woodward R et al:The effect of prescribed daily dose frequency on patient medication compliance. Arch Int Med 150:1881-1884, 1990

• 8) Caroline MS, Michelle IW:Milnacipran. A review of its use in depression. Drugs 56:405-427, 1998

• 9) Ansseau M, Papart P, Troisfontaines B et al:Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 114:131-137, 1994
  pubmed

• 10) Lopez IJ, Guelfi JD, Pletan Y et al:Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacot 11 (Suppl 4):41-46, 1996

• 11) 渡辺昌祐, 横山茂生:抗うつ薬の選び方と使い方 (改訂版). 新興医学出版社, 東京, p114-115, 1993

• 12) 北海道臨床精神薬理研究会 (会長 山下 格):塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価-塩酸イミプラミンを対照薬とした第III相試験-. 臨床医薬 11:121-144, 1995

• 13) Briley M:Specific serotonin and noradrenaline reuptake inhibitor (SNRI). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol 13:99-111, 1998

• 14) 田島 治:SNRIの相互作用と副作用. 臨床精神薬理 3:353-361, 2000

• 15) Preskorn SH:Antidepressant drug selection:criteria and options. J Clin Psychiatry 55 (Suppl A):6-22, 1994

• 16) Susan LM, Paul EK, Loren MF:Minimizing and managing antidepressant side effect. J Clin Psychiatry 56 (Suppl 2):49-55, 1995

P.277 掲載の参考文献

• 1) Briley M:Milnacipran:A well-tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressant. CNS Drug Rev 4:137-148, 1998.

• 2) 警察庁生活安全局地域課:平成12年中における自殺の概要資料. 2001

• 3) Kielholz P:Diagnose und Therapie der Depressionen fur den Praktiker, 3. Aufl, Lehmanns, Munchen, 1974

• 4) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran:An overview. Int Clin Psychopharmacol 11 (Suppl 4):47-51, 1996

• 5) 村崎光邦:Milnacipranの基礎と臨床. 臨床精神薬理 3:363-380, 2000

• 6) Poldinger W:Die Abschutzung der Suizidalitat, Huber, Bern, 1968

• 7) Roose SP, Glassman AH, Walsh BT et al:Depression, delusion, and suicide. Am J Psychiatry 140:1159-1162, 1983
  pubmed

• 8) 佐野光一, 中澤哲也, 矢野譲次ほか:抗うつ薬ミルナシプランの安全性に関する研究 (第1報):ラットと猿を用いた急性毒性試験. 基礎と臨床 28:3089-3107, 1994

• 9) 融道男:向精神薬マニュアル第2版. 医学書院, 2001

• 10) 高橋祥友:自殺の危険;臨床的評価と危機介入. 金剛出版, 1992

• 11) Takahashi Y, Hirasawa H, Koyama K et al:Suicide and aging in Japan:an examination of treated elderly suicide attempters. Int Psychogeriatr 7:239-251, 1995
  pubmed

• 12) 高橋祥友:自殺の心理学. 講談社, 1997

• 13) 高橋祥友:群発自殺. 中央公論社, 1998

• 14) 高橋祥友:老年期うつ病. 日本評論社, 1998

• 15) 高橋祥友:青少年のための自殺予防マニュアル. 金剛出版, 1999

• 16) 高橋祥友:自殺のサインを読みとる. 講談社, 2001

P.287 掲載の参考文献

• 1) Artigas F:Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). Pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs 4:79-89, 1995

• 2) Beekman AT, Copeland JR, Prince MJ:Review of community prevalence of depression in later life. Br J Psychiatry 174:307-311, 1999
  pubmed

• 3) Brubacher JR, Hoffman RS, Lurin MJ:Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol 38:358-361, 1996
  pubmed

• 4) Briley M:Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol Clin Exp 13:99-111, 1998

• 5) Caron J, Libersa C, Hazard JR et al:Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 3:493-500, 1993
  pubmed

• 6) Dierick M:An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8:169-178, 1996

• 7) Entsuah AR, Rudolph RL, Chitra R:Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients:a meta-analysis. Psychopharmacol Bull 31:759-766, 1995

• 8) Fantaskey A, Burkhart KK:A case report of venlafaxine toxicity. J Toxicol Clin Toxicol 33:359-361, 1995
  pubmed

• 9) Hindmarch I, Rigney U, Stanley N et al:Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 49:118-125, 2000

• 10) Hodgman MJ, Martin TG, Krenzelok EP:Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 16:14-17, 1997
  pubmed

• 11) Holliday SM, Benfield P:Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294, 1995
  pubmed

• 12) Iliffe S, Haines A, Gallivan S et al:Assessment of elderly people in general practice. 1. Social circumstances and mental state. Br J Gen Pract 41:9-12, 1991
  pubmed

• 13) Ishigooka J, Murasaki M, LY248686 study group:First open study with anti-depressant LY 248686 (Duloxetine) for depression in Japan [abstract]. 20th Collegium International Neuropsychopharmacologium Congress, Melbourne, 1996

• 14) Kasper S, Pletan Y, Solles A et al:Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression:a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl 4):35-39, 1996

• 15) 熊谷敬一, 須賀良一, 小熊隆夫ほか:新発田市市川東地区における在宅老人のうつ病と痴呆の疫学調査:有病率と1年予後. 臨床精神医学21:1483-1490, 1992

• 16) MacDonald AJ:ABC of mental health. Mental health in old age. Br Med J 315:413-417, 1998

• 17) Mahapatra SN, Hackett D:A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 51:209-213, 1997

• 18) 松原良次, 小野寺勇夫, 伊藤公一ほか:塩酸ミルナシプラン (TN-912) のうつ病, うつ状態に対する薬効評価-塩酸イミプラミンを対照薬とした第III相臨床試験-. 臨床医薬 11:819-842, 1995
  Medical*Online

• 19) Mekler G, Woggon B:A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry 30:272-273, 1997
  pubmed

• 20) Montgomery SA, Prost JF, Solles A et al:Efficacy and tolerability of milnacipran:an overview. Int Clin Psychopharmacol 11 (Suppl 4):47-51, 1996

• 21) 森田昌宏, 須賀良一, 内藤明彦ほか:老人自殺多発地域における老年期うつ病の疫学調査. 社会精神医学 10:132-137, 1987

• 22) 中道 昇, 関野久之, 及村昌臣ほか:高齢者における塩酸ミルナシプランの薬物動態の検討. 臨床医薬 11 (Suppl 3):133-153, 1995

• 23) 大森健一:老年期うつ病. 治療 59:1550-1554, 2001

• 24) Puozzo C, Deville G, Bromet-Petit M et al:Single dose pharmacokinetics of F2207, a new antidepressant drug, in elderly volunteers [abstract]. Symposium on variability in pharmacokinetcs and drug response. Gothenburg, Sweden, 1988

• 25) Puozzo C, Leonard BE:Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psycholpharmacol 11 (Suppl 4):15-27, 1996

• 26) Ranieri P, Franzoni S, Rozzini R et al:Venlafaxine-induced reset osmostat syndrome:case of a 79-year-old depressed woman. J Geriatr Psychiatry Neurol 10:75-78, 1997
  pubmed

• 27) Rouet RH, Tisne-Versailles J, Adamantidis MM et al:Comparative in vivo and in vitro study of the cardiac effects of milnacipran and imipramine. Fundam Clin Pharmacol 3:237-244, 1989
  pubmed

• 28) Shrivastava RK, Cohn C, Crowder J et al:Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14:322-329, 1994
  pubmed

• 29) Spencer CM, Wilde MI:Milnacipran:a review of its use in depression. Drugs 56:405-427, 1998
  pubmed

• 30) 高橋明比古, 村崎光邦, 稲見充明ほか:新規抗うつ薬塩酸ミルナシプランの高齢者に対する臨床的有用性の検討. 臨床医薬11 (Suppl 3):103-118, 1995

• 31) 高橋三郎:老年期のうつ病の経過と予後. 老年精神医学雑誌 6:285-292, 1995
  Medical*Online

• 32) Takahashi Y, Hirasawa H, Koyama K et al:Suicide and aging in Japan:an examination of treated elderly suicide attempters. Int Psychogeriatr 7:239-251, 1995
  pubmed

• 33) 田所千代子, 宮岡 等, 上島国利:うつ病の遷延化要因長期入院患者による検討. 精神医学 43:185-193, 2001

• 34) Teicher MH, Glod C, Cole JO:Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210, 1990
  pubmed

• 35) Tignol J, Pujol-Domenech J, Chartres Jp et al:Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 97:157-165, 1998
  pubmed

• 36) van Walraven C, Mamdani MM, Wells PS et al:Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients:retrospective cohort study. Br Med J 323:655-658, 2001

• 37) 和田雄治:SNRI系抗うつ・尿失禁治療薬塩酸デュロキセチン. 脳の科学 20:921-926, 1998

• 38) Weissman MM, Myers JK:Affective disorders in a US urban community. Arch Gen Psychiatry 35:1304-1311, 1978